Original Article
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
N Engl J Med 2009; 361:2209-2220December 3, 2009
- Abstract
Background
The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control.
Methods
In a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial, we evaluated four priming injections of a recombinant canarypox vector vaccine (ALVAC-HIV [vCP1521]) plus two booster injections of a recombinant glycoprotein 120 subunit vaccine (AIDSVAX B/E). The vaccine and placebo injections were administered to 16,402 healthy men and women between the ages of 18 and 30 years in Rayong and Chon Buri provinces in Thailand. The volunteers, primarily at heterosexual risk for HIV infection, were monitored for the coprimary end points: HIV-1 infection and early HIV-1 viremia, at the end of the 6-month vaccination series and every 6 months thereafter for 3 years.
Results
In the intention-to-treat analysis involving 16,402 subjects, there was a trend toward the prevention of HIV-1 infection among the vaccine recipients, with a vaccine efficacy of 26.4% (95% confidence interval [CI], −4.0 to 47.9; P=0.08). In the per-protocol analysis involving 12,542 subjects, the vaccine efficacy was 26.2% (95% CI, −13.3 to 51.9; P=0.16). In the modified intention-to-treat analysis involving 16,395 subjects (with the exclusion of 7 subjects who were found to have had HIV-1 infection at baseline), the vaccine efficacy was 31.2% (95% CI, 1.1 to 52.1; P=0.04). Vaccination did not affect the degree of viremia or the CD4+ T-cell count in subjects in whom HIV-1 infection was subsequently diagnosed.
Conclusions
This ALVAC-HIV and AIDSVAX B/E vaccine regimen may reduce the risk of HIV infection in a community-based population with largely heterosexual risk. Vaccination did not affect the viral load or CD4+ count in subjects with HIV infection. Although the results show only a modest benefit, they offer insight for future research. (ClinicalTrials.gov number, NCT00223080.)
Media in This Article
Figure 1
Enrollment and Outcomes.Figure 2
Kaplan–Meier Cumulative Rates of Infection, According to Type of Analysis.Article Activity
- Article
In the late 1980s in Thailand, there was a dramatic increase in the prevalence of infection with the human immunodeficiency virus type 1 (HIV-1) in sentinel surveillance cohorts.1-3 Initially, these groups consisted of injection-drug users and commercial sex workers; they were subsequently expanded to include persons in the general population. By 1995, the overall seroprevalence of HIV-1 reached a peak of 3.7% among conscripts in the Royal Thai Army and of 12.5% among conscripts from Northern Thailand.2,4,5 The Thai Ministry of Public Health responded with an effective HIV-prevention campaign, and the number of new HIV-1 infections per year decreased from an estimated 143,000 in 1990 to 14,000 in 2007.2,4,6-9 The persistence of new infection despite these measures led public health officials to conclude that an HIV vaccine, within the context of a broader HIV-prevention program, was needed for better control of the epidemic.
A number of trials of various subtype B canarypox–HIV vector primes and boosters containing subunit glycoprotein 120 or 160 (gp120 or gp160) established the prime–boost concept as a candidate for advanced testing.10-13 Canarypox-based prime–boost regimens induced both cellular and humoral responses, but CD8+ responses on enzyme-linked immunosorbent spot (ELISPOT) assay were low,12 and the presence of primary isolate neutralizing antibody was not consistently detected.14-18
A series of phase 1 and 2 trials of HIV vaccines involving more than 1000 Thai volunteers was undertaken, with products matching the circulating HIV-1 subtypes B and CRF01_AE.8,17-22 Although a phase 3 trial of VaxGen bivalent gp120 AIDSVAX B/E vaccine alone involving injection-drug users showed no effect on HIV-1 acquisition,21 a phase 2 trial of an ALVAC-HIV (vCP1521) prime with an AIDSVAX B/E boost showed induction of prespecified cellular and humoral immune responses and was consistent with criteria for advancement to a large test-of-concept study.17 In October 2003, our study was initiated in a population at community risk for HIV infection.8
Methods
Study Design and Population
This study was a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial of the prime–boost combination of vaccines containing ALVAC-HIV (vCP1521) (Sanofi Pasteur) and AIDSVAX B/E (Global Solutions for Infectious Diseases). For details regarding the vaccines and placebo, see the Supplementary Appendix, available with the full text of this article at NEJM.org. The study was designed to evaluate two coprimary end points: the prevention of HIV-1 infection and the effect of vaccination on the early viral load after infection. The trial was conducted through facilities of the Thai Ministry of Public Health in Rayong and Chon Buri provinces. From September 2003 through December 2005, a total of 16,402 volunteers were enrolled.
Thai men and women who were between the ages of 18 and 30 years and who were not infected with HIV were recruited from the community without regard to HIV risk (i.e., community risk). Written informed consent was obtained from all volunteers, who were required to pass a written test of understanding. Women were counseled to practice effective contraception until 3 months after the last vaccination; pregnant and breast-feeding women were excluded.
Study Oversight
The protocol was reviewed by the ethics committees of the Ministry of Public Health, the Royal Thai Army, Mahidol University, and the Human Subjects Research Review Board of the U.S. Army Medical Research and Materiel Command. It was also independently reviewed and endorsed by the World Health Organization and the Joint United Nations Program on HIV/AIDS and by the AIDS Vaccine Research Working Group of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. The manufacturers were full trial collaborators and were a part of the phase 3 trial steering committee.
Study Procedures
The study vaccines were administered at baseline (day 0), 4 weeks (prespecified range, 3 to 7), 12 weeks (range, 10 to 15), and 24 weeks (range, 21 to 28). The ALVAC-HIV (vCP1521) vaccine was administered at each of the four visits. Boosting with AIDSVAX B/E occurred at weeks 12 and 24. For 3 days after each dose of vaccine, subjects reported local and systemic vaccine reactions on a diary card. All other adverse and serious adverse events were documented at each visit and were graded on a scale that is used for rating adverse events associated with vaccines, as recommended by the Division of Acquired Immunodeficiency Syndrome of the National Institute of Allergy and Infectious Diseases (http://rcc.tech-res.com/safetyandpharmacovigilance). All subjects who underwent randomization were included in the safety analysis.
Women underwent urine testing for pregnancy throughout the vaccination phase. Pregnant volunteers did not receive further vaccinations. All volunteers were followed with the use of HIV testing at day 0, at 24 and 26 weeks, and every 6 months during the 3-year follow-up phase. Peripheral-blood mononuclear cells were isolated and archived in liquid nitrogen at 0, 6, 12, and 42 months. Assessment of behavior associated with an increased risk of HIV infection occurred at baseline, at week 26, and at each 6-month follow-up visit. HIV-prevention counseling was provided during each vaccination and post-test counseling visit.
Primary End Points
We established the presence of HIV infection on the basis of repeated positive results on enzyme immunoassay and Western blotting, with two confirmatory HIV nucleic acid tests: the Amplicor HIV Monitor (version 1.5) assay (Roche) in Thailand and the Procleix HIV discriminatory assay (Novartis) in the United States. We performed three measurements of HIV-1 RNA within 6 weeks after serodiagnosis to determine the mean postinfection viral load. Infection time was defined as the midpoint between the last negative result and the first positive result of testing. An independent end-points monitoring committee whose members were unaware of study-group assignments verified the accuracy of all diagnoses.
Assessment of Risk
We assessed subjects' risk of HIV infection using a self-administered behavioral questionnaire at baseline and every 6 months thereafter. First, volunteers categorized themselves as being at high, moderate, or low risk for HIV infection. A second approach categorized subjects as being at high risk if they reported being at high risk or reported any high-risk behavior (e.g., needle sharing, multiple sex partners, commercial sex work, and symptoms of sexually transmitted disease). Volunteers were considered to be at low risk if they perceived their risk as low; if they reported that in the previous 6 months they had had no more than one sex partner and no sexual contact with a commercial sex worker, a partner of the same sex, an HIV-infected partner, a partner who used injection drugs, or a partner who had multiple partners; and if they reported having had no symptoms of a sexually transmitted disease or incarceration within 6 months before study entry. Moderate-risk subjects were considered to be at neither low nor high risk.
Immunogenicity Analyses
We analyzed plasma and cells from volunteers who did not have HIV infection at various time points after vaccination to evaluate immunogenicity. After removal of a small subgroup of samples for future matched case–control studies, we identified random samples and provided them in a blinded fashion to the Armed Forces Research Institute of Medical Sciences laboratory at a ratio of samples from the vaccine group to samples from the placebo group of approximately 4:1. The immunogenicity of the vaccine regimen was measured with the use of the following validated assays: interferon-γ ELISPOT and CD4+ and CD8+ intracellular cytokine staining for interferon-γ and interleukin-2 to Gag and Env; binding antibody to gp120 in the MN strain, gp120 in the A244 strain (CM244), and p24 Gag; and lymphoproliferation to gp120 MN, gp120 A244, and p24 (for details, see the Supplementary Appendix).17,18,22-25
Statistical Analysis
According to the study protocol, we conducted both intention-to-treat and per-protocol analyses. The intention-to-treat analysis included all subjects who underwent randomization. Because of the time between screening and vaccination and the possibility of acquiring HIV-1 infection during this interval, the protocol specified look-back testing of baseline plasma for HIV-1 RNA if the sample that was collected on the day of the fourth vaccination was HIV-seropositive. Seven persons who were enrolled and vaccinated were found to be positive for HIV-1 RNA at baseline. The per-protocol analysis included a subgroup of subjects in the intention-to-treat analysis who received the entire series of vaccinations within the defined time period, who remained eligible to participate in the study, and who did not have HIV infection at the time of the fourth vaccination. A separate subgroup analysis, called the modified intention-to-treat analysis, excluded the seven volunteers who were found to have HIV infection at baseline. This was used as the primary analysis at the time of the interim and final analyses and was prespecified in the final data-analysis plan that was approved 5 months before the unblinding of the study. (For details regarding the sample size calculation, randomization procedures, and calculation of vaccine efficacy, see the Supplementary Appendix.)
After the initiation of the trial, the effect of vaccination on early viral load was included as a coprimary end point, and the mean postinfection viral load was compared between vaccine and placebo recipients at the 1% level with the Wilcoxon statistic. The effect of selection bias was considered.26
The trial was monitored by an independent, international data and safety monitoring board, which met every 6 to 12 months (eight times during the trial) and reviewed the trial for safety and futility. At the interim analysis, the trial was reviewed for efficacy, safety, and futility. Statistical futility for the acquisition end point was examined with a trigger for early termination if the conditional power was less than 10%. All reported P values are two-tailed and have not been adjusted for multiple testing. A P value of less than 0.05 was considered to indicate statistical significance.
Results
Study Population
A total of 26,676 volunteers were screened and 16,402 were enrolled (intention-to-treat group) (Figure 1Figure 1
Enrollment and Outcomes.). The 12,542 subjects who completed all vaccination visits on schedule and were not found to have HIV-1 infection after receiving the full vaccination regimen were included in the per-protocol analysis. Seven volunteers who were found to be seropositive for HIV-1 on the first test after vaccination were determined by RNA testing to have been infected at enrollment and were not included in the modified intention-to-treat analysis, leaving 16,395 volunteers: 8197 in the vaccine group and 8198 in the placebo group. This group consisted of 10,064 men (61.4% of the subjects) and 6331 women (38.6%). Baseline characteristics were similar for selected variables, and there was no imbalance between the two groups in self-described risk behavior (Table 1Table 1
Baseline Characteristics of the Subjects (Modified Intention-to-Treat Population).).There were no substantive changes in serial self-reports of risk behavior during the trial. No data were collected on the status of male circumcision or on serologic analyses for adenovirus type 5 or herpes simplex virus type 2.
There were 52,985 person-years of follow-up (15% more than planned). At 42 months, 14,672 of the volunteers (89.5%) had completed the trial and were HIV-seronegative.
Adverse Events
Most local and systemic reactions to the vaccine were mild to moderate and reflected the findings of studies on the safety of these products that have been reported previously12,17,27-29 (Fig. 1 in the Supplementary Appendix). Most reactions were mild to moderate and resolved within 3 days after vaccination. At least one adverse event was reported in 69.4% of subjects in the two study groups. The number of deaths and the frequency and severity of adverse events and serious adverse events were similar in the two groups (Table 1 in the Supplementary Appendix).
Primary End Points
HIV-1 Infection
HIV-1 infection was diagnosed in 132 subjects (56 in the vaccine group and 76 in the placebo group) during 52,985 person-years of follow-up in the intention-to-treat analysis, in 86 subjects (36 in the vaccine group and 50 in the placebo group) during 36,720 person-years of follow-up in the per-protocol analysis, and in 125 subjects (51 in the vaccine group and 74 in the placebo group) during 52,985 person-years of follow-up in the modified intention-to-treat analysis. One subject in the placebo group who was identified by hospital record as being seropositive for HIV after dying from Pneumocystis jirovecii pneumonia was included in the analysis before the unblinding of the study. This diagnosis of HIV-1 infection was the only one that occurred outside planned procedures.
With the use of the Cox proportional-hazards method, the observed vaccine efficacy was 26.4% (95% confidence interval [CI], −4.0 to 47.9; P=0.08) in the intention-to-treat analysis (Figure 2AFigure 2
Kaplan–Meier Cumulative Rates of Infection, According to Type of Analysis.); 26.2% (95% CI, −13.3 to 51.9; P=0.16) in the per-protocol analysis (Figure 2B); and 31.2% (95% CI, 1.1 to 52.1; P=0.04 by the O'Brien–Fleming method) in the modified intention-to-treat analysis (Figure 2C). Because HIV testing was done at week 24, it is not possible to discern which dose of vaccine might have been associated with an early effect. The overall observed effect in the modified intention-to-treat analysis was evaluated with the use of several different analyses: event rates by Barnard's test (P=0.04), the log-rank test (P=0.04), the Wilcoxon test (P=0.03), modification of the time-to-seroconversion end point (P=0.04), exclusion of the in-hospital diagnosed case (P=0.05), and analysis of interval-censored data (P=0.04).Covariates were analyzed for the populations with similar results. Simultaneous adjustment for sex, age, living with a partner, and baseline risk factors did not affect estimates of vaccine efficacy, even though between-group differences in age, living with a partner, and baseline risk factors were significant. Subgroup analyses revealed no significant heterogeneity in vaccine efficacy according to baseline variables (Table 2Table 2
Rate of HIV Infection and Vaccine Efficacy, According to Selected Baseline Variables (Modified Intention-to-Treat Population).).There were 86 HIV-1 infections in the per-protocol population and 125 infections in the modified intention-to-treat population. There were three categories into which the 39 subjects with HIV-1 infection who were excluded from the per-protocol population could be organized: 10 subjects (3 in the vaccine group and 7 in the placebo group) were infected during the vaccination phase and received all vaccinations on schedule; 10 subjects (3 in the vaccine group and 7 in the placebo group) were infected after the vaccination phase and received all vaccinations, but one or more vaccinations were not administered during the prespecified window; and 19 subjects (9 in the vaccine group and 10 in the placebo group) were infected after the vaccination phase but did not receive all vaccinations.
Postinfection Viral Load and CD4+ T-Cell Count
There was no significant difference in the mean viral load among subjects who were found to have HIV infection in the vaccine group, as compared with those in the placebo group. The mean viral-load values were 4.36 log10 copies per milliliter in the vaccine group and 4.21 log10 copies per milliliter in the placebo group (P=0.09 by the Wilcoxon test) in the intention-to-treat analysis (Figure 3Figure 3
Viral Loads in Subjects with Early HIV-1 Infection.). The viral-load values were 4.24 log10 copies per milliliter in the vaccine group and 4.19 log10 copies per milliliter in the placebo group in the per-protocol analysis (P=0.47) and 4.30 log10 copies per milliliter and 4.20 log10 copies per milliliter, respectively, in the modified intention-to-treat analysis (P=0.24).In all three analyses, there were no significant between-group differences in postinfection CD4+ T-cell counts. The mean early postinfection CD4+ T-cell count was 541 cells per microliter in the vaccine group and 568 cells per microliter in the placebo group in the intention-to-treat analysis (P=0.47 by the Wilcoxon test), 572 cells per microliter in the vaccine group and 532 cells per microliter in the placebo group in the per-protocol analysis (P=0.72), and 555 cells per microliter in the vaccine group and 568 cells per microliter in the placebo group in the modified intention-to-treat analysis (P=0.76).
Immunogenicity
Vaccination induced an HIV-specific response, as measured by the production of interferon-γ by T cells when exposed to either Env or Gag antigen on ELISPOT assay, in 19.7% of volunteers 6 months after the final dose of vaccine was administered (Table 3Table 3
Immunogenicity Analyses at Baseline and 12 Months. and the Supplementary Appendix). This result was similar to the rate of 17% in the phase 2 trial (de Souza MS: personal communication). Response rates for CD4+ Env-specific intracellular cytokine staining were higher in the vaccine group than in the placebo group. Rates of positivity in the gp120 and p24 binding-antibody assays and the lymphoproliferation assay were similar to those in the phase 2 study.17 Binding antibody for Env was nearly uniformly present, with the reciprocal of the geometric mean titer (GMT−1) of 31,207 for the MN strain and 14,558 for the A244 strain, whereas p24 responses were less frequent (GMT−1, 138) (for details, see the Supplementary Appendix). The median lymphocyte stimulation index (LSI) was 2 for all subjects at baseline and subsequently in placebo recipients. The LSI was significantly higher in vaccine recipients (median LSI, 24 for gp120 MN, 32 for A244, and 4 for p24).Discussion
In this clinical trial, we evaluated the efficacy of ALVAC-HIV priming and AIDSVAX B/E boosting for the prevention of HIV-1 infection in more than 16,000 young Thai adults at community risk for such infection. In the intention-to-treat group (which included seven subjects who were found to have had HIV-1 infection at baseline), there was a trend toward prevention of infection with the vaccine regimen. In the per-protocol analysis, which excluded 30% of the end points and person-years of follow-up, the results were not significant. However, after the exclusion of the subjects who were infected with HIV-1 before vaccination, the modified intention-to-treat analysis showed a significant, though modest, reduction in the rate of HIV-1 infection, as compared with placebo.
Taken together, these data are consistent with a modest protective effect of vaccine in this study. However, there was no significant difference in the HIV-1 viral load or the postinfection CD4+ count between the two study groups. A simple, combined analysis of phase 1 and 2 ALVAC-HIV and gp120 prime–boost studies showed a rate of HIV-1 infection of 0.59 per 100 person-years in the vaccine group and 1.2 per 100 person-years in the placebo group, for a vaccine efficacy of 50% (95% CI, −39 to 80), a difference that was not significant; the results also showed no effect on viral load.30 In nonhuman primates, ALVAC-SIV appeared to protect neonatal macaques against infection from milk containing a low dose of simian immunodeficiency virus (SIV).31 However, ALVAC-SIV did not prevent infection from a more intense challenge exposure, although it did reduce the viral load and delay disease progression.32,33
Our trial did not have sufficient power to determine whether there was an effect of risk stratification on either disease acquisition or vaccine efficacy, and none of the observed heterogeneity achieved significance. Previous efficacy trials of HIV vaccines in higher-risk populations have not shown an effect on disease acquisition. Bivalent subtype B AIDSVAX B/B gp120 did not protect high-risk men who have sex with men,34-36 and AIDSVAX B/E did not protect Thai injection-drug users21 from infection with HIV-1. The Step trial of Merck recombinant adenovirus type 5 (rAd5) HIV-1 vaccine containing subtype B gag, pol, and nef in high-risk men who have sex with men was stopped because of futility and possibly higher rates of infection in vaccine recipients.37
An immunologic correlate with protection from HIV-1 infection has not been determined at this time. Though early studies of canarypox–gp120 subunit prime–boost regimens were promising,10-13 advanced-phase testing of subtype B ALVAC-HIV (vCP1452) and AIDSVAX B/B was canceled because CD8+ reactivity on ELISPOT was too low.12 The vaccines that were used in our trial showed a level of immunogenicity that was similar to levels reported previously.17 Additional studies with the use of more recently developed immunogenicity assays are planned in order to determine their suitability for correlates analyses.38-41 Further insight may be gained through molecular-sieve analysis of breakthrough infections with the use of single-genome amplification.42
Although our study provided preliminary evidence that an HIV vaccine regimen has the potential to prevent infection, it did not have the power to address two intriguing considerations: vaccine efficacy may have decreased over the first year after vaccination, and vaccine efficacy may have been greater in persons at lower risk for infection (Figure 2 and Table 2). These issues deserve greater attention in future studies. We do not understand the immune mechanisms mediating the results that we observed. The ALVAC-HIV and AIDSVAX B/E prime–boost regimen induces a broad constellation of immune responses against HIV-1, including T-cell–line adapted neutralizing antibody (71% with response), antibody-directed, cell-mediated cytotoxicity, CD4+ lymphoproliferation (61% with response to gp20 MN, 63% with response to gp120 CM244), and CD8+ T cells (24% with response to 51Cr-release cytotoxic T-cell assay; 17% with positive response on ELISPOT),17,33,43 but these may not be the relevant responses. Understanding the potential immunologic correlates of protection will be a principal research focus. The data also do not answer the related question of whether it was a single vaccine or the combination of vaccines that induced a potentially protective immune response. Previous studies have suggested that prime–boost combinations induce qualitative or quantitative protective immune responses that are not seen with either vaccine alone, but the current data do not address this question.28,44
Finally, our study supports the possibility that immunologic mechanisms mediating protection against HIV may be different from those mediating early postinfection control of viral replication.45,46 Taken together, these considerations underscore the opportunities afforded by the efficacy testing of HIV vaccines in human subjects in providing an objective context for review of existing methods of vaccine design, immunogenicity testing, and animal models.
Supported in part by an Interagency Agreement (Y1-AI-2642-12) between the U.S. Army Medical Research and Materiel Command and the National Institute of Allergy and Infectious Diseases and by a cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine and the U.S. Department of Defense. Sanofi Pasteur provided the ALVAC-HIV vaccine, and Global Solutions for Infectious Diseases (VaxGen) provided the reagents for the immunogenicity assays.
The opinions expressed in this article are those of the authors and do not represent the official views of the Department of Health and Human Services, the National Institute of Allergy and Infectious Diseases, the Centers for Disease Control and Prevention, the Department of Defense, or Department of the Army.
Drs. Gurunathan, Tartaglia, and McNeil report being employees of Sanofi Pasteur, and Dr. Tartaglia reports having an equity interest in the company. No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0908492) was published on October 20, 2009, and was last updated on November 19, 2009, at NEJM.org.
We thank the volunteers who participated in this study and staff members of the Ministry of Public Health at health centers in Rayong, Chon Buri, and surrounding provinces.
Source Information
From the Department of Disease Control, Ministry of Public Health, Nonthaburi (S.R.-N., R.P., C.N., S.C., C.K., P.T., P.K.); Vaccine Trials Center (P.P.) and Data Management Unit (J.K.), Faculty of Tropical Medicine, Mahidol University, Bangkok; Thai Component (S.N.) and U.S. Army Medical Component (J.C., R.P., M.S., M.B.), Armed Forces Research Institute of Medical Sciences, Bangkok — all in Thailand; the Division of AIDS, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD (E.A.); Sanofi Pasteur, Swiftwater, PA (S.G., J.T., J.G.M.); Global Solutions for Infectious Diseases, South San Francisco, CA (D.P.F.); the Emmes Corporation, Rockville, MD (D.S.); the Global AIDS Program, Centers for Disease Control and Prevention, Atlanta (D.L.B.); U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Rockville, MD (M.L.R., N.L.M., J.H.K.); and U.S. Army Medical Materiel Development Activity, Ft. Detrick, MD (J.H.K.).
Address reprint requests to Dr. Kim at the U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 1600 E. Gude Dr., Rockville, MD 20850, or at jkim@hivresearch.org.
The names and affiliations of the Ministry of Public Health–Thai AIDS Vaccine Evaluation Group (MOPH–TAVEG) investigators are listed in the Appendix.
Appendix
The following investigators and institutions participated in the MOPH-TAVEG study: Ministry of Public Health, Thailand: S. Rerks-Ngarm, S. Chunsuttiwat, N. Premsri, C. Namwat, P. Kunasol, P. Thongcharoen, C. Khamboonruang; Vaccine Trials Center, Mahidol University: P. Pitisuttithum, V. Bussaratid, W. Maek-a-nantawat, J. Dhitavat, P. Suntharasamai, S. Pungpak, S. Vanijanonta; Data Management Unit, Mahidol University: J. Kaewkunwal, A. Khamsiriwatchara, P. Jarujareet; Royal Thai Army, Armed Forces Research Institute of Medical Sciences: S. Nitayaphan, C. Easmila, S. Tabprasit; U.S. Army Component, Armed Forces Research Institute of Medical Sciences: J. Chiu, R. Paris, M. Benenson, A. Brown, P. Morgan, M. de Souza, R. Trichavaroj, A. Schuetz, N. Thaitawat; Sanofi Pasteur: S. Gurunathan, J. Tartaglia, J.G. McNeil, R. Harkness, C. Meric, R. El Habib, L. Baglyos; Global Solutions in Infectious Diseases: D. Francis, C. Lee; National Institute of Allergy and Infectious Diseases: E. Adams; U.S. Military HIV Research Program, Walter Reed Army Institute of Research and U.S. Army Medical Materiel Development Agency, U.S. Army Medical Research and Materiel Command: J.H. Kim, M.L. Robb, N.L. Michael, M. Milazzo, A. Bolen, B. Wessner, S.R. Kim, M. Marovich, J. Currier; Global AIDS Program, Centers for Disease Control and Prevention: D.L. Birx; Emmes Corporation: D. Stablein, T. Germanson, L. Dally; SHI Consulting: R. Wiley; International AIDS Vaccine Initiative: Dr. J.-L. Excler; Tripler Army Medical Center: Dr. J. Berenberg.
- References
References
1
Brown T ,Peerapatanapokin W . The Asian epidemic model: a process model for exploring HIV policy and programme alternatives in Asia. Sex Transm Infect 2004;80:Suppl 1:i19-i24
CrossRef | Web of Science | Medline2
Phoolcharoen W . HIV/AIDS prevention in Thailand: success and challenges. Science 1998;280:1873-1874
CrossRef | Web of Science | Medline3
Weniger BG ,Limpakarnjanarat K ,Ungchusak K , et al. The epidemiology of HIV infection and AIDS in Thailand. AIDS 1991;5:S71-S85[Erratum, AIDS 1993;7:following 147.]
CrossRef | Medline4
Nelson KE ,Celentano DD ,Eiumtrakol S , et al. Changes in sexual behavior and a decline in HIV infection among young men in Thailand. N Engl J Med 1996;335:297-303
Full Text | Web of Science | Medline5
Nitayaphan S ,Brown AE . Preventive HIV vaccine development in Thailand. AIDS1998;S155-S161
Medline6
Hanenberg RS ,Rojanapithayakorn W ,Kunasol P ,Sokal DC . Impact of Thailand's HIV-control programme as indicated by the decline of sexually transmitted diseases. Lancet 1994;344:243-245
CrossRef | Web of Science | Medline7
Nelson KE ,Celentano DD ,Suprasert S , et al. Risk factors for HIV infection among young adult men in northern Thailand. JAMA 1993;270:955-960
CrossRef | Web of Science | Medline8
Rerks-Ngarm S ,Brown AE ,Khamboonruang C ,Thongcharoen P ,Kunasol P . HIV/AIDS preventive vaccine `prime-boost' phase III trial: foundations and initial lessons learned from Thailand. AIDS 2006;20:1471-1479
CrossRef | Web of Science | Medline9
National AIDS Prevention and Alleviation Committee. UNGASS country progress report: Thailand. Reporting Period January 2006 - December 2007. (Accessed October 19, 2009, at http://data.unaids.org/pub/Report/2008/thailand_2008_country_progress_report_en.pdf.)
10
Belshe RB ,Gorse GJ ,Mulligan MJ , et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 1998;12:2407-2415
CrossRef | Web of Science | Medline11
Belshe RB ,Graham BS ,Keefer MC , et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994;272:475-480
CrossRef | Web of Science | Medline12
Russell ND ,Graham BS ,Keefer MC , et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 2007;44:203-212
CrossRef | Web of Science | Medline13
The AIDS Vaccine Evaluation Group 022 Protocol Team
CrossRef | Web of Science | Medline14
Mascola JR ,Snyder SW ,Weislow OS , et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996;173:340-348
CrossRef | Web of Science | Medline15
Verrier F ,Burda S ,Belshe R , et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show intercalde cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates. J Virol 2000;74:10025-10033
CrossRef | Web of Science | Medline16
Zolla-Pazner S ,Xu S ,Burda S ,Duliege AM ,Excler JL ,Clements-Mann ML . Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines. J Infect Dis 1998;178:1502-1506
CrossRef | Web of Science | Medline17
Nitayaphan S ,Pitisuttithum P ,Karnasuta C , et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 2004;190:702-706
CrossRef | Web of Science | Medline18
Thongcharoen P ,Suriyanon V ,Paris RM , et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007;46:48-55
CrossRef | Web of Science | Medline19
Nitayaphan S ,Khamboonruang C ,Sirisophana N , et al. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. Vaccine 2000;18:1448-1455
CrossRef | Web of Science | Medline20
Pitisuttithum P ,Berman PW ,Phonrat B , et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr 2004;37:1160-1165[Erratum, J Acquir Immune Defic Syndr 2004;37:1669.]
CrossRef | Web of Science | Medline21
Pitisuttithum P ,Gilbert P ,Gurwith M , et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194:1661-1671
CrossRef | Web of Science | Medline22
Pitisuttithum P ,Nitayaphan S ,Thongcharoen P , et al. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis 2003;188:219-227
CrossRef | Web of Science | Medline23
Kibuuka H, Kimutai R, Maboko L, et al. A phase I/II study of a multiclade HIV-1 DNA plasmid prime and recombinant Adenovirus-type 5 boost vaccine in HIV uninfected East Africans. J Infect Dis (in press).
24
Currier JR ,Kuta EG ,Turk E , et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002;260:157-172
CrossRef | Web of Science | Medline25
Fu TM ,Dubey SA ,Mehrotra DV , et al. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res Hum Retroviruses 2007;23:67-76
CrossRef | Web of Science | Medline26
Gilbert PB ,Bosch RJ ,Hudgens MG . Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics 2003;59:531-541
CrossRef | Web of Science | Medline27
Belshe RB ,Stevens C ,Gorse GJ , et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001;183:1343-1352
CrossRef | Web of Science | Medline28
Clements-Mann ML ,Weinhold K ,Matthews TJ , et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998;177:1230-1246
CrossRef | Web of Science | Medline29
Gupta K ,Hudgens M ,Corey L , et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002;29:254-261
Web of Science | Medline30
Lee D ,Graham BS ,Chiu YL , et al. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 2004;190:903-907
CrossRef | Web of Science | Medline31
Van Rompay KK ,Abel K ,Lawson JR , et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 2005;38:124-134
CrossRef | Web of Science | Medline32
Pal R ,Venzon D ,Letvin NL , et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 2002;76:292-302
CrossRef | Web of Science | Medline33
Pal R ,Venzon D ,Santra S , et al. Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol 2006;80:3732-3742
CrossRef | Web of Science | Medline34
Gilbert PB ,Ackers ML ,Berman PW , et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 2005;192:974-983
CrossRef | Web of Science | Medline35
Gilbert PB ,Peterson ML ,Follmann D , et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005;191:666-677
CrossRef | Web of Science | Medline36
Flynn NM ,Forthal DN ,Harro CD ,Judson FN ,Mayer KH ,Para MF . Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191:654-665
CrossRef | Web of Science | Medline37
Buchbinder SP ,Mehrotra DV ,Duerr A , et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-1893
CrossRef | Web of Science | Medline38
Mascola JR ,D'Souza P ,Gilbert P , et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005;79:10103-10107
CrossRef | Web of Science | Medline39
Forthal DN ,Gilbert PB ,Landucci G ,Phan T . Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007;178:6596-6603
Web of Science | Medline40
McElrath MJ ,De Rosa SC ,Moodie Z , et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008;372:1894-1905
CrossRef | Web of Science | Medline41
Seder RA ,Darrah PA ,Roederer M . T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008;8:247-258[Erratum, Nat Rev Immunol 2008;8:486.]
CrossRef | Web of Science | Medline42
Salazar-Gonzalez JF ,Salazar MG ,Keele BF , et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009;206:1273-1289
CrossRef | Web of Science | Medline43
Karnasuta C ,Paris RM ,Cox JH , et al. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005;23:2522-2529
CrossRef | Web of Science | Medline44
Ratto-Kim S ,Loomis-Price LD ,Aronson N , et al. Comparison between env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults. J Acquir Immune Defic Syndr 2003;32:9-17
CrossRef | Web of Science | Medline45
Alter G ,Teigen N ,Ahern R , et al. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis 2007;195:1452-1460
CrossRef | Web of Science | Medline46
Goonetilleke N ,Liu MK ,Salazar-Gonzalez JF , et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009;206:1253-1272
CrossRef | Web of Science | Medline
- Citing Articles (305)
Citing Articles
1
Erik De Clercq. (2012) Pre-exposure chemoprophylaxis of HIV infection: Quo vadis?. Biochemical Pharmacology 83:5, 567-573
CrossRef2
Lyle R. McKinnon, Rupert Kaul. (2012) Quality and quantity. Current Opinion in HIV and AIDS 7:2, 195-202
CrossRef3
Louis J. Picker, Scott G. Hansen, Jeffrey D. Lifson. (2012) New Paradigms for HIV/AIDS Vaccine Development. Annual Review of Medicine 63:1, 95-111
CrossRef4
Margaret E. Ackerman, Anne-Sophie Dugast, Galit Alter. (2012) Emerging Concepts on the Role of Innate Immunity in the Prevention and Control of HIV Infection. Annual Review of Medicine 63:1, 113-130
CrossRef5
Ramesh S. Paranjape, Madhuri R. Thakar, Manisha V. Ghate, Sheela V. Godbole. (2012) Current Status of Research on HIV Epidemic, Pathogenesis, Management and Prevention in India. Proceedings of the National Academy of Sciences, India Section B: Biological Sciences
CrossRef6
Basile Siewe, Alan Landay. (2012) Key Concepts in the Early Immunology of HIV-1 Infection. Current Infectious Disease Reports 14:1, 102-109
CrossRef7
Nawal Ben Haij, Olfa Mzoughi, Rémi Planès, Elmostafa Bahraoui. (2012) Cationic nanoglycolipidic particles as vector and adjuvant for the study of the immunogenicity of SIV Nef protein. International Journal of Pharmaceutics 423:1, 116-123
CrossRef8
Eduardo Castro-Nallar, Marcos Pérez-Losada, Gregory F. Burton, Keith A. Crandall. (2012) The evolution of HIV: Inferences using phylogenetics. Molecular Phylogenetics and Evolution 62:2, 777-792
CrossRef9
J. P. Williams, J. Frater. (2012) Current understanding in HIV immunopathology and treatment. QJM
CrossRef10
Kaushik Bharati, Sudhanshu Vrati. (2012) Viral Vaccines in India: An Overview. Proceedings of the National Academy of Sciences, India Section B: Biological Sciences
CrossRef11
Dan H. Barouch, Jinyan Liu, Hualin Li, Lori F. Maxfield, Peter Abbink, Diana M. Lynch, M. Justin Iampietro, Adam SanMiguel, Michael S. Seaman, Guido Ferrari, Donald N. Forthal, Ilnour Ourmanov, Vanessa M. Hirsch, Angela Carville, Keith G. Mansfield, Donald Stablein, Maria G. Pau, Hanneke Schuitemaker, Jerald C. Sadoff, Erik M. Billings, Mangala Rao, Merlin L. Robb, Jerome H. Kim, Mary A. Marovich, Jaap Goudsmit, Nelson L. Michael. (2012) Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature
CrossRef12
Nelson L. Michael. (2012) Rare serotype adenoviral vectors for HIV vaccine development. Journal of Clinical Investigation 122:1, 25-27
CrossRef13
Sarah C. Gilbert. (2012) T-cell-inducing vaccines - what’s the future. Immunology 135:1, 19-26
CrossRef14
Marc H. V. Regenmortel. (2012) Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Archives of Virology 157:1, 1-20
CrossRef15
Peter A Newman. (2012) Integrating social and biomedical science in HIV vaccine research: obstacles, opportunities and ways forward. Expert Review of Vaccines 11:1, 1-3
CrossRef16
Josephine H. Cox, Maria G. Ferrari, Patricia Earl, James R. Lane, Linda L. Jagodzinski, Victoria R. Polonis, Ellen G. Kuta, Jean D. Boyer, Silvia Ratto-Kim, Leigh-Anne Eller, Doan-Trang Pham, Lydia Hart, David Montefiori, Guido Ferrari, Stephanie Parrish, David B. Weiner, Bernard Moss, Jerome H. Kim, Deborah Birx, Thomas C. VanCott. (2012) Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. Vaccine
CrossRef17
Christopher A. Todd, Kelli M. Greene, Xuesong Yu, Daniel A. Ozaki, Hongmei Gao, Yunda Huang, Maggie Wang, Gary Li, Ronald Brown, Blake Wood, M. Patricia D'Souza, Peter Gilbert, David C. Montefiori, Marcella Sarzotti-Kelsoe. (2012) Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. Journal of Immunological Methods 375:1-2, 57-67
CrossRef18
Robert A. Rasmussen, Nagadenahalli B. Siddappa, Samir K. Lakhashe, Jennifer Watkins, François Villinger, Chris Ibegbu, Ruth H. Florese, Marjorie Robert-Guroff, David C. Montefiori, Donald N. Forthal, David O’Connor, Ruth M. Ruprecht. (2012) High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure. AIDS 26:2, 149-155
CrossRef19
Koen K.A. Van Rompay. (2012) The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies. AIDS Research and Human Retroviruses 28:1, 16-35
CrossRef20
Jacques Fellay, Amalio Telenti. 2012. Genetic Associations with Resistance to HIV-1 Infection, Viral Control and Protection Against Disease. , 319-334.
CrossRef21
Andrew J. Mouland, Miroslav P. Milev. 2012. Role of Dynein in Viral Pathogenesis. , 560-583.
CrossRef22
Elias K. Haddad, Giuseppe Pantaleo. (2012) Systems biology in the development of HIV vaccines. Current Opinion in HIV and AIDS 7:1, 44-49
CrossRef23
Maximillian Rosario, Nicola Borthwick, Guillaume B. Stewart-Jones, Alice Mbewe-Mvula, Anne Bridgeman, Stefano Colloca, David Montefiori, Andrew J. McMichael, Alfredo Nicosia, Esther D. Quakkelaar, Jan W. Drijfhout, Cornelis J.M. Melief, Tomáš Hanke. (2012) Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS 26:3, 275-284
CrossRef24
Rafick Sekaly, Bali Pulendran. (2012) Systems biology in understanding HIV pathogenesis and guiding vaccine development. Current Opinion in HIV and AIDS 7:1, 1-3
CrossRef25
Marc P. Girard, Stanley A. Plotkin. (2012) HIV vaccine development at the turn of the 21st century. Current Opinion in HIV and AIDS 7:1, 4-9
CrossRef26
Helder I. Nakaya, Bali Pulendran. (2012) Systems vaccinology. Current Opinion in HIV and AIDS 7:1, 24-31
CrossRef27
Justin J. O’Hagan, Miguel A. Hernán, Rochelle P. Walensky, Marc Lipsitch. (2012) Apparent declining efficacy in randomized trials. AIDS 26:2, 123-126
CrossRef28
Daniel E. Zak, Alan Aderem. (2012) Overcoming limitations in the systems vaccinology approach. Current Opinion in HIV and AIDS 7:1, 58-63
CrossRef29
Erica Andersen-Nissen, Antje Heit, M. Juliana McElrath. (2012) Profiling immunity to HIV vaccines with systems biology. Current Opinion in HIV and AIDS 7:1, 32-37
CrossRef30
Austin Pantel, Cheolho Cheong, Durga Dandamudi, Elina Shrestha, Saurabh Mehandru, Luke Brane, Darren Ruane, Angela Teixeira, Leonia Bozzacco, Ralph M. Steinman, M. Paula Longhi. (2012) A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo. European Journal of Immunology 42:1, 101-109
CrossRef31
Joris Hemelaar. (2012) The origin and diversity of the HIV-1 pandemic. Trends in Molecular Medicine
CrossRef32
Robert Paris, Sasitorn Bejrachandra, Prasert Thongcharoen, Sorachai Nitayaphan, Punnee Pitisuttithum, Anna Sambor, Sanjay Gurunathan, Donald Francis, Silvia Ratto-Kim, Chitraporn Karnasuta, Mark S. de Souza, Victoria R. Polonis, Arthur E. Brown, Jerome H. Kim, Henry A. Stephens. (2012) HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX® B/E. Vaccine 30:5, 832-836
CrossRef33
Jun Yong Choi, June Myung Kim. (2012) Updates on the prevention and treatment of AIDS. Journal of the Korean Medical Association 55:2, 146
CrossRef34
Ann J. Hessell, Nancy L. Haigwood. (2011) Neutralizing Antibodies and Control of HIV: Moves and Countermoves. Current HIV/AIDS Reports
CrossRef35
J. M. Marrazzo, W. Cates. (2011) Interventions to Prevent Sexually Transmitted Infections, Including HIV Infection. Clinical Infectious Diseases 53:suppl 3, S64-S78
CrossRef36
Sergio Rosales-Mendoza, Néstor Rubio-Infante, Dania O. Govea-Alonso, Leticia Moreno-Fierros. (2011) Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV). Plant Cell Reports
CrossRef37
Susan Moir, Angela Malaspina, Anthony S Fauci. (2011) Prospects for an HIV vaccine: leading B cells down the right path. Nature Structural & Molecular Biology 18:12, 1317-1321
CrossRef38
Fernando Maltêz, Manuela Doroana, Teresa Branco, Cristina Valente. (2011) Recent advances in antiretroviral treatment and prevention in HIV-infected patients. Current Opinion in HIV and AIDS 6, S21-S30
CrossRef39
Cecilia T Costiniuk, Jonathan B Angel. (2011) ALVAC-HIV as a prophylactic and therapeutic vaccine: highlights from over a decade of clinical trials. Future Virology 6:12, 1481-1492
CrossRef40
Thomas C. Quinn. (2011) The 30-Year War on AIDS: Have We Reached the Tipping Point?. Sexually Transmitted Diseases 38:12, 1089-1093
CrossRef41
Francisco Antunes. (2011) Antiretroviral therapy for naïve and for treatment-experienced HIV patients, and prevention of HIV transmission. Current Opinion in HIV and AIDS 6, S1-S2
CrossRef42
Ronald O. Valdiserri. (2011) Commentary: Thirty Years of AIDS in America: A Story of Infinite Hope. AIDS Education and Prevention 23:6, 479-494
CrossRef43
Tomáš Hanke, Andrew J. McMichael. (2011) HIV-1: From escapism to conservatism. European Journal of Immunology 41:12, 3390-3393
CrossRef44
Richard Hopkins, Anne Bridgeman, Charles Bourne, Alice Mbewe-Mvula, Jerald C. Sadoff, Gerald W. Both, Joan Joseph, John Fulkerson, Tomáš Hanke. (2011) Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. European Journal of Immunology 41:12, 3542-3552
CrossRef45
M. Scott Killian, Jay A. Levy. (2011) HIV/AIDS: 30 Years of progress and future challenges. European Journal of Immunology 41:12, 3401-3411
CrossRef46
Salim S Abdool Karim, Quarraisha Abdool Karim. (2011) Antiretroviral prophylaxis: a defining moment in HIV control. The Lancet 378:9809, e23-e25
CrossRef47
Izabela Bialuk, Stephen Whitney, Vibeke Andresen, Ruth H. Florese, Janos Nacsa, Valentina Cecchinato, Valerio W. Valeri, Jean-Michel Heraud, Shari Gordon, Robyn Washington Parks, David C. Montefiori, David Venzon, Thorsten Demberg, Marjorie Robert- Guroff, Gary Landucci, Donald N. Forthal, Genoveffa Franchini. (2011) Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. Vaccine 30:1, 78-94
CrossRef48
Lynne M. Mofenson. (2011) Prevention of Mother-to-Child HIV-1 Transmission—Why We Still Need a Preventive HIV Immunization Strategy. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:4, 359-362
CrossRef49
G.J.V. Nossal. (2011) Vaccines of the future. Vaccine
CrossRef50
Girish N. Vyas, Cheryl A. Stoddart, M. Scott Killian, Todd V. Brennan, Tiffany Goldberg, Alyssa Ziman, Yvonne Bryson. (2011) Derivation of non-infectious envelope proteins from virions isolated from plasma negative for HIV antibodies. Biologicals
CrossRef51
F. K. Sawe. (2011) Access to Universal HIV Care and Prevention Services: Light at the End of a Long Tunnel?. Clinical Infectious Diseases
CrossRef52
Lisa M. McDaid, Graham J. Hart. (2011) Willingness to Participate in Future HIV Prevention Studies Among Gay and Bisexual Men in Scotland, UK: A Challenge for Intervention Trials. AIDS and Behavior
CrossRef53
L. R. Baden, W. A. Blattner, C. Morgan, Y. Huang, O. D. Defawe, M. E. Sobieszczyk, N. Kochar, G. D. Tomaras, M. J. McElrath, N. Russell, K. Brandariz, M. Cardinali, B. S. Graham, D. H. Barouch, R. Dolin, . (2011) Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects. Journal of Infectious Diseases 204:10, 1541-1549
CrossRef54
E. H. J. G. Aarntzen, M. Srinivas, J. H. W. De Wilt, J. F. M. Jacobs, W. J. Lesterhuis, A. D. Windhorst, E. G. Troost, J. J. Bonenkamp, M. M. van Rossum, W. A. M. Blokx, R. D. Mus, O. C. Boerman, C. J. A. Punt, C. G. Figdor, W. J. G. Oyen, I. J. M. de Vries. (2011) Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging. Proceedings of the National Academy of Sciences 108:45, 18396-18399
CrossRef55
A. Burgener, S. Rahman, R. Ahmad, J. Lajoie, S. Ramdahin, C. Mesa, S. Brunet, C. Wachihi, J. Kimani, K. Fowke, S. Carr, F. Plummer, T. B. Ball. (2011) Comprehensive Proteomic Study Identifies Serpin and Cystatin Antiproteases as Novel Correlates of HIV-1 Resistance in the Cervicovaginal Mucosa of Female Sex Workers. Journal of Proteome Research 10:11, 5139-5149
CrossRef56
Joseph C. Forbi, Peter E. Entonu, Lulu O. Mwangi, Simon M. Agwale. (2011) Estimates of human immunodeficiency virus incidence among female sex workers in north central Nigeria: implications for HIV clinical trials. Transactions of the Royal Society of Tropical Medicine and Hygiene 105:11, 655-660
CrossRef57
John Goulding, Vikas Tahiliani, Shahram Salek-Ardakani. (2011) OX40:OX40L axis: emerging targets for improving poxvirus-based CD8+ T-cell vaccines against respiratory viruses. Immunological Reviews 244:1, 149-168
CrossRef58
John Stover. (2011) 30 years after HIV identification: where to from here?. Expert Review of Anti-infective Therapy 9:11, 947-949
CrossRef59
Wayne C. Koff. (2011) HIV vaccine development: Challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Vaccine
CrossRef60
Ji Wang, Liling Xu, Pei Tong, Ying-Hua Chen. (2011) Mucosal antibodies induced by tandem repeat of 2F5 epitope block transcytosis of HIV-1. Vaccine 29:47, 8542-8548
CrossRef61
Diego A. Vargas-Inchaustegui, Thorsten Demberg, Marjorie Robert-Guroff. (2011) A CD8α− subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities. Immunology 134:3, 326-340
CrossRef62
Dobromir T. Dimitrov, Marie-Claude Boily, Rebecca F. Baggaley, Benoit Masse. (2011) Modeling the gender-specific impact of vaginal microbicides on HIV transmission. Journal of Theoretical Biology 288, 9-20
CrossRef63
Chintan Chhatbar, Ritu Mishra, Ashish Kumar, Sunit Kumar Singh. (2011) HIV vaccine: hopes and hurdles. Drug Discovery Today 16:21-22, 948-956
CrossRef64
Beryl A. Koblin, Gordon Mansergh, Victoria Frye, Hong Van. Tieu, Donald R. Hoover, Sebastian Bonner, Stephen A. Flores, Sharon M. Hudson, Grant N. Colfax. (2011) Condom-Use Decision Making in the Context of Hypothetical Pre-Exposure Prophylaxis Efficacy Among Substance-Using Men Who Have Sex With Men. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:3, 319-327
CrossRef65
Jennifer Serwanga, Susan Mugaba, Edward Pimego, Bridget Nanteza, Fred Lyagoba, Susan Nakubulwa, Laura Heath, Rebecca N. Nsubuga, Nicaise Ndembi, Frances Gotch, Pontiano Kaleebu. (2011) Profile of T Cell Recognition of HIV Type 1 Consensus Group M Gag and Nef Peptides in a Clade A1- and D-Infected Ugandan Population. AIDS Research and Human Retroviruses111017082114005
CrossRef66
G. J. V. Nossal. (2011) Vaccines and future global health needs. Philosophical Transactions of the Royal Society B: Biological Sciences 366:1579, 2833-2840
CrossRef67
B. Greenwood, D. Salisbury, A. V. S. Hill. (2011) Vaccines and global health. Philosophical Transactions of the Royal Society B: Biological Sciences 366:1579, 2733-2742
CrossRef68
G. J. Nabel, P. D. Kwong, J. R. Mascola. (2011) Progress in the rational design of an AIDS vaccine. Philosophical Transactions of the Royal Society B: Biological Sciences 366:1579, 2759-2765
CrossRef69
Thomas J Hope. (2011) Moving ahead an HIV vaccine: To neutralize or not, a key HIV vaccine question. Nature Medicine 17:10, 1195-1197
CrossRef70
Bruce D Walker, Rafi Ahmed, Stanley Plotkin. (2011) Moving ahead an HIV vaccine: Use both arms to beat HIV. Nature Medicine 17:10, 1194-1195
CrossRef71
Susanne E. Johansson, Erik Rollman, Amy W. Chung, Rob J. Center, Bo Hejdeman, Ivan Stratov, Jorma Hinkula, Britta Wahren, Klas Kärre, Stephen J. Kent, Louise Berg. (2011) NK Cell Function and Antibodies Mediating ADCC in HIV-1-Infected Viremic and Controller Patients. Viral Immunology 24:5, 359-368
CrossRef72
Kennedy N Otwombe, Kathleen J Sikkema, Janan Dietrich, Guy de Bruyn, Martin van der Watt, Glenda E Gray. (2011) Willingness to Participate in Biomedical HIV Prevention Studies After the HVTN 503/Phambili Trial: A Survey Conducted Among Adolescents in Soweto, South Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:2, 211-218
CrossRef73
Erin L Lousberg, Kerrilyn R Diener, Michael P Brown, John D Hayball. (2011) Innate immune recognition of poxviral vaccine vectors. Expert Review of Vaccines 10:10, 1435-1449
CrossRef74
J.R. Abbott, M.P. Sanou, J.K. Coleman, J.K. Yamamoto. (2011) Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine. Veterinary Immunology and Immunopathology 143:3-4, 246-254
CrossRef75
Natalie A Hutnick, Devin JF Myles, Chaoran Billie Bian, Karuppiah Muthumani, David B Weiner. (2011) Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Current Opinion in Virology 1:4, 233-240
CrossRef76
Samir K Lakhashe, Guido Silvestri, Ruth M Ruprecht. (2011) No acquisition: A new ambition for HIV vaccine development?. Current Opinion in Virology 1:4, 246-253
CrossRef77
Felipe García, Juan Carlos López Bernaldo de Quirós, Carmen E. Gómez, Beatriz Perdiguero, Jose L. Nájera, Victoria Jiménez, Juan García-Arriaza, Alberto C. Guardo, Iñaki Pérez, Vicens Díaz-Brito, Matilde Sánchez Conde, Nuria González, Amparo Alvarez, José Alcamí, José Luis Jiménez, Judit Pich, Joan Albert Arnaiz, María J. Maleno, Agathe León, María Angeles Muñoz-Fernández, Peter Liljeström, Jonathan Weber, Giuseppe Pantaleo, José M. Gatell, Montserrat Plana, Mariano Esteban. (2011) Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine 29:46, 8309-8316
CrossRef78
Paul Swain. (2011) Future Innovative Therapies to Treat Upper Gastrointestinal Bleeding. Gastrointestinal Endoscopy Clinics of North America 21:4, 739-747
CrossRef79
Hildegund Ertl, Bali Pulendran. (2011) Editorial overview. Current Opinion in Virology 1:4, 223-225
CrossRef80
Thomas Mourez, Mariana Mesel-Lemoine, Chantal Combredet, Valérie Najburg, Nadège Cayet, Frédéric Tangy. (2011) A chimeric measles virus with a lentiviral envelope replicates exclusively in CD4+/CCR5+ cells. Virology 419:2, 117-125
CrossRef81
Muhammad Bakari, Said Aboud, Charlotta Nilsson, Joel Francis, Deus Buma, Candida Moshiro, Eric A. Aris, Eligius F. Lyamuya, Mohamed Janabi, Karina Godoy-Ramirez, Agricola Joachim, Victoria R. Polonis, Andreas Bråve, Patricia Earl, Merlin Robb, Mary Marovich, Britta Wahren, Kisali Pallangyo, Gunnel Biberfeld, Fred Mhalu, Eric Sandström. (2011) Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 29:46, 8417-8428
CrossRef82
Amy W Chung, Marjon Navis, Gamze Isitman, Leia Wren, Julie Silvers, Janaki Amin, Stephen J Kent, Ivan Stratov. (2011) Activation of NK Cells by ADCC Antibodies and HIV Disease Progression. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:2, 127-131
CrossRef83
Amanda L Harrison, Stephen Henry, Radhia Mahfoud, Adam Manis, Aurelie Albertini, Yves Gaudin, Clifford A Lingwood, Donald R Branch. (2011) A novel VSV/HIV pseudotype approach for the study of HIV microbicides without requirement for level 3 biocontainment. Future Virology 6:10, 1241-1259
CrossRef84
Wendy A. Burgers, Amapola Manrique, David Masopust, Lyle R. McKinnon, Matthew R. Reynolds, Morgane Rolland, Catherine Blish, Gerald K. Chege, Rhonda Curran, William Fischer, Carolina Herrera, D. Noah Sather. (2011) Measurements of Immune Responses for Establishing Correlates of Vaccine Protection Against HIV. AIDS Research and Human Retroviruses110923090450004
CrossRef85
David L. Blazes, Kevin L. Russell. (2011) Medicine in war and peace: Joining forces. Nature 477:7365, 395-396
CrossRef86
Jose M Martinez-Navio, Nuria Climent, Teresa Gallart, Carme Lluis, Rafael Franco. (2011) An old enzyme for current needs: adenosine deaminase and a dendritic cell vaccine for HIV. Immunology and Cell Biology
CrossRef87
Ewen Callaway. (2011) Clues emerge to explain first successful HIV vaccine trial. Nature
CrossRef88
Johnston, Margaret I., Fauci, Anthony S., . (2011) HIV Vaccine Development — Improving on Natural Immunity. New England Journal of Medicine 365:10, 873-875
Full Text89
Peter A. Newman, Carmen Logie, LLana James, Tamicka Charles, John Maxwell, Khaled Salam, Michael Woodford. (2011) “Speaking the Dialect”: Understanding Public Discourse in the Aftermath of an HIV Vaccine Trial Shutdown. American Journal of Public Health 101:9, 1749-1758
CrossRef90
Yves Lévy. (2011) Perpetuation of vaccine memory T cell responses against SIV/HIV. EMBO Molecular Medicine 3:9, 507-509
CrossRef91
Lucia Lopalco, Morgane Bomsel. (2011) Protecting the initial site of viral entry: an alternative HIV vaccine target. Expert Review of Vaccines 10:9, 1253-1256
CrossRef92
Yoshiaki Nishimura, Malcolm A Martin. (2011) The acute HIV infection: implications for intervention, prevention and development of an effective AIDS vaccine. Current Opinion in Virology 1:3, 204-210
CrossRef93
Ennio De Gregorio, Rino Rappuoli. (2011) Vaccines for the future: learning from human immunology. Microbial Biotechnologyno-no
CrossRef94
Leolin Katsidzira, James G. Hakim. (2011) HIV prevention in southern Africa: why we must reassess our strategies?. Tropical Medicine & International Health 16:9, 1120-1130
CrossRef95
Paolo Palma, Maria Luisa Romiti, Giuseppina Li Pira, Carla Montesano, Nadia Mora, Angela Aquilani, Veronica Santilli, Hyppolite K. Tchidjou, Federico Ivaldi, Luigi Giovannelli, Giuseppe Pontrelli, Giada Borra, Pontus Blomberg, Lindvi Gudmundsdotter, Andreas Bråve, Marco Montano, Stefania Bernardi, Fabrizio Manca, Britta Wahren, Paolo Rossi. (2011) The PEDVAC trial: Preliminary data from the first therapeutic DNA vaccination in HIV-infected children. Vaccine 29:39, 6810-6816
CrossRef96
Larisa I. Karpenko, Alexey V. Danilenko, Sergei I. Bazhan, Elena D. Danilenko, Galina M. Sysoeva, Olga N. Kaplina, Olga Y. Volkova, Svetlana F. Oreshkova, Alexander A. Ilyichev. (2011) Attenuated Salmonella enteritidis E23 as a vehicle for the rectal delivery of DNA vaccine coding for HIV-1 polyepitope CTL immunogen. Microbial Biotechnologyno-no
CrossRef97
Cecilia Cheng-Mayer, Yaoxing Huang, Agegnehu Gettie, Lily Tsai, Wuze Ren, Madina Shakirzyanova, Silvana T. Sina, Nataliya Trunova, James Blanchard, Lisa M. Miller Jenkins, Yungtai Lo, Marco L. Schito, Ettore Appella. (2011) Delay of simian human immunodeficiency virus infection and control of viral replication in vaccinated macaques challenged in the presence of a topical microbicide. AIDS 25:15, 1833-1841
CrossRef98
Rada Ellegård, Esaki M. Shankar, Marie Larsson. (2011) Targeting HIV-1 innate immune responses therapeutically. Current Opinion in HIV and AIDS 6:5, 435-443
CrossRef99
Andrea Gorlani, Joachim Brouwers, Christopher McConville, Pieter van der Bijl, Karl Malcolm, Patrick Augustijns, Anna Forsman Quigley, Robin Weiss, Hans De Haard, Theo Verrips. (2011) Llama Antibody Fragments Have Good Potential for Application as HIV Type 1 Topical Microbicides. AIDS Research and Human Retroviruses110824074857001
CrossRef100
Paula M. Frew, Matthew Archibald, Brooke Hixson, Carlos del Rio. (2011) Socioecological influences on community involvement in HIV vaccine research. Vaccine 29:36, 6136-6143
CrossRef101
Haitham Ghunaim, Ashok Kumar, Jose Torres, Francisco Diaz-Mitoma, Ali Azizi. (2011) An immunological comparison between lipidated and non-lipidated multivalent HIV-1 peptides representing Gp120 and Gag hypervariable regions. Vaccine 29:35, 5950-5958
CrossRef102
Elisa F. Long, Douglas K. Owens. (2011) The cost-effectiveness of a modestly effective HIV vaccine in the United States. Vaccine 29:36, 6113-6124
CrossRef103
Erin E. West, Ben Youngblood, Wendy G. Tan, Hyun-Tak Jin, Koichi Araki, Gabriela Alexe, Bogumila T. Konieczny, Silvia Calpe, Gordon J. Freeman, Cox Terhorst, W. Nicholas Haining, Rafi Ahmed. (2011) Tight Regulation of Memory CD8+ T Cells Limits Their Effectiveness during Sustained High Viral Load. Immunity 35:2, 285-298
CrossRef104
Denis R Chopera, Jaclyn K Wright, Mark A Brockman, Zabrina L Brumme. (2011) Immune-mediated attenuation of HIV-1. Future Virology 6:8, 917-928
CrossRef105
B. Ferraro, M. P. Morrow, N. A. Hutnick, T. H. Shin, C. E. Lucke, D. B. Weiner. (2011) Clinical Applications of DNA Vaccines: Current Progress. Clinical Infectious Diseases 53:3, 296-302
CrossRef106
Justin Pollara, Lydia Hart, Faraha Brewer, Joy Pickeral, Beverly Z. Packard, James A. Hoxie, Akira Komoriya, Christina Ochsenbauer, John C. Kappes, Mario Roederer, Ying Huang, Kent J. Weinhold, Georgia D. Tomaras, Barton F. Haynes, David C. Montefiori, Guido Ferrari. (2011) High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry Part A 79A:8, 603-612
CrossRef107
Lawrence R. Stanberry, Richard Strugnell. (2011) Vaccines of the future. Perspectives in Vaccinology 1:1, 151-199
CrossRef108
Kyeen M. Andersson, John Stover. (2011) The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand. Vaccine 29:36, 6092-6099
CrossRef109
Rogier W Sanders. (2011) Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine. Expert Review of Vaccines 10:8, 1117-1122
CrossRef110
Samir K. Lakhashe, Vijayakumar Velu, Gaia Sciaranghella, Nagadenahalli B. Siddappa, Janet M. DiPasquale, Girish Hemashettar, John K. Yoon, Robert A. Rasmussen, Feng Yang, Sandra J. Lee, David C. Montefiori, Francis J. Novembre, François Villinger, Rama Rao Amara, Maria Kahn, Shiu-Lok Hu, Sufen Li, Zhongxia Li, Fred R. Frankel, Marjorie Robert-Guroff, Welkin E. Johnson, Judy Lieberman, Ruth M. Ruprecht. (2011) Prime–boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: Efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine 29:34, 5611-5622
CrossRef111
Nico J.D. Nagelkerke, Jan A.C. Hontelez, Sake J. de Vlas. (2011) The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: A modeling study. Vaccine 29:36, 6079-6085
CrossRef112
Sunee Sirivichayakul, Pattarawat Thantiworasit, Pornsupa Chatkulkawin, Supranee Buranapraditkun, Mee Ling Munier, Anthony D. Kelleher, Kiat Ruxrungtham. (2011) Immunogenicity assay validation for an HIV vaccine trial: High IFNγ+/IL-2+ CD8+ T cells background in healthy Thais. Vaccine 29:35, 6002-6007
CrossRef113
Catherine A. Hankins, John W. Glasser, Robert T. Chen. (2011) Modeling the impact of RV144-like vaccines on HIV transmission. Vaccine 29:36, 6069-6071
CrossRef114
Jan A.C. Hontelez, Nico Nagelkerke, Till Bärnighausen, Roel Bakker, Frank Tanser, Marie-Louise Newell, Mark N. Lurie, Rob Baltussen, Sake J. de Vlas. (2011) The potential impact of RV144-like vaccines in rural South Africa: A study using the STDSIM microsimulation model. Vaccine 29:36, 6100-6106
CrossRef115
Kyeen M. Andersson, A. David Paltiel, Douglas K. Owens. (2011) The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results. Vaccine 29:36, 6107-6112
CrossRef116
Robert T. Chen, Dale J. Hu, Eileen Dunne, Michael Shaw, James I. Mullins, Supachai Rerks-Ngarm. (2011) Preparing for the availability of a partially effective HIV vaccine: Some lessons from other licensed vaccines. Vaccine 29:36, 6072-6078
CrossRef117
Marc P. Girard, Saladin Osmanov, Olga M. Assossou, Marie-Paule Kieny. (2011) Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review. Vaccine 29:37, 6191-6218
CrossRef118
Stephen R Walsh, Raphael Dolin. (2011) Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Review of Vaccines 10:8, 1221-1240
CrossRef119
Karen Schneider, Cliff C. Kerr, Alexander Hoare, David P. Wilson. (2011) Expected epidemiological impacts of introducing an HIV vaccine in Thailand: A model-based analysis. Vaccine 29:36, 6086-6091
CrossRef120
Richard T. Gray, Mohammad H. Ghaus, Alexander Hoare, David P. Wilson. (2011) Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia. Vaccine 29:36, 6125-6129
CrossRef121
D. R. Burton, A. J. Hessell, B. F. Keele, P. J. Klasse, T. A. Ketas, B. Moldt, D. C. Dunlop, P. Poignard, L. A. Doyle, L. Cavacini, R. S. Veazey, J. P. Moore. (2011) Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proceedings of the National Academy of Sciences 108:27, 11181-11186
CrossRef122
Maarten F. Schim van der Loeff, Alan G. Nyitray, Anna R. Giuliano. (2011) HPV Vaccination to Prevent HIV Infection: Time for Randomized Controlled Trials. Sexually Transmitted Diseases 38:7, 640-643
CrossRef123
Laurent Bélec, Mohammad-Ali Jenabian, Charlotte Charpentier, Hela Saïdi. (2011) Combinatorial prevention of HIV transmission in women: the case for a vaginal microbicide. Future Microbiology 6:7, 731-737
CrossRef124
Merlin Robb. (2011) HIV vaccine development: a new beginning. Expert Review of Vaccines 10:7, 925-927
CrossRef125
Nancy S Padian, Sandra I McCoy, Salim S Abdool Karim, Nina Hasen, Julia Kim, Michael Bartos, Elly Katabira, Stefano M Bertozzi, Bernhard Schwartländer, Myron S Cohen. (2011) HIV prevention transformed: the new prevention research agenda. The Lancet 378:9787, 269-278
CrossRef126
J. A. Hanley. (2011) Measuring Mortality Reductions in Cancer Screening Trials. Epidemiologic Reviews 33:1, 36-45
CrossRef127
L. Lai, S. Kwa, P. A. Kozlowski, D. C. Montefiori, G. Ferrari, W. E. Johnson, V. Hirsch, F. Villinger, L. Chennareddi, P. L. Earl, B. Moss, R. R. Amara, H. L. Robinson. (2011) Prevention of Infection by a Granulocyte-Macrophage Colony-Stimulating Factor Co-Expressing DNA/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. Journal of Infectious Diseases 204:1, 164-173
CrossRef128
Harry Kaltsidis, Hannah Cheeseman, Jakub Kopycinski, Ambreen Ashraf, Michelle Cashin Cox, Lorna Clark, Insiyah Anjarwalla, Len Dally, Phillip Bergin, Aggeliki Spentzou, Chris Higgs, Frances Gotch, Brian Gazzard, Raul Gomez, Peter Hayes, Peter Kelleher, Dilbinder K. Gill, Jill Gilmour. (2011) Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trials. Journal of Immunological Methods 370:1-2, 43-54
CrossRef129
Bette Korber. (2011) Building on the past to define an efficient path to an HIV vaccine. Expert Review of Vaccines 10:7, 929-931
CrossRef130
Anne-Sophie Dugast, Andrew Tonelli, Christoph T. Berger, Margaret E. Ackerman, Gaia Sciaranghella, Qingquan Liu, Magdalena Sips, Ildiko Toth, Alicja Piechocka-Trocha, Musie Ghebremichael, Galit Alter. (2011) Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology 415:2, 160-167
CrossRef131
R. J. Shattock, M. Warren, S. McCormack, C. A. Hankins. (2011) Turning the Tide Against HIV. Science 333:6038, 42-43
CrossRef132
Luca Cassetta, Guido Poli, Massimo Alfano. 2011. HIV and Cytokines. , 139-153.
CrossRef133
Bali Pulendran, Rafi Ahmed. (2011) Immunological mechanisms of vaccination. Nature Immunology 131:6, 509-517
CrossRef134
Jean-Louis Excler, Wasima Rida, Frances Priddy, Jill Gilmour, Adrian B. McDermott, Anatoli Kamali, Omu Anzala, Gaudensia Mutua, Eduard J. Sanders, Wayne Koff, Seth Berkley, Patricia Fast. (2011) AIDS Vaccines and Preexposure Prophylaxis: Is Synergy Possible?. AIDS Research and Human Retroviruses 27:6, 669-680
CrossRef135
(2011) Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148). Vaccine 29:25, 4285-4292
CrossRef136
Donald R Branch. (2011) Role of G protein-coupled vasoactive intestinal peptide receptors in HIV integration. Future Virology 6:6, 741-753
CrossRef137
Christine S Rollier, Arturo Reyes-Sandoval, Matthew G Cottingham, Katie Ewer, Adrian VS Hill. (2011) Viral vectors as vaccine platforms: deployment in sight. Current Opinion in Immunology 23:3, 377-382
CrossRef138
S. De Flora, P. Bonanni. (2011) The prevention of infection-associated cancers. Carcinogenesis 32:6, 787-795
CrossRef139
Michael M. Thomson, Aurora Fernández-García. (2011) Phylogenetic structure in African HIV-1 subtype C revealed by selective sequential pruning. Virology 415:1, 30-38
CrossRef140
Mark W. Hull, Julio Montaner. (2011) Antiretroviral Therapy: A Key Component of a Comprehensive HIV Prevention Strategy. Current HIV/AIDS Reports 8:2, 85-93
CrossRef141
J. B. F. de Wit, P. Aggleton, T. Myers, M. Crewe. (2011) The rapidly changing paradigm of HIV prevention: time to strengthen social and behavioural approaches. Health Education Research 26:3, 381-392
CrossRef142
Tinevimbo Shiri, Alex Welte. (2011) Modelling the impact of acute infection dynamics on the accumulation of HIV-1 mutations. Journal of Theoretical Biology 279:1, 44-54
CrossRef143
Corie Lok. (2011) Vaccines: His best shot. Nature 473:7348, 439-441
CrossRef144
Rino Rappuoli, Alan Aderem. (2011) A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473:7348, 463-469
CrossRef145
N. L. Letvin, S. S. Rao, D. C. Montefiori, M. S. Seaman, Y. Sun, S.-Y. Lim, W. W. Yeh, M. Asmal, R. S. Gelman, L. Shen, J. B. Whitney, C. Seoighe, M. Lacerda, S. Keating, P. J. Norris, M. G. Hudgens, P. B. Gilbert, A. P. Buzby, L. V. Mach, J. Zhang, H. Balachandran, G. M. Shaw, S. D. Schmidt, J.-P. Todd, A. Dodson, J. R. Mascola, G. J. Nabel. (2011) Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Science Translational Medicine 3:81, 81ra36-81ra36
CrossRef146
A. W. Chung, G. Isitman, M. Navis, M. Kramski, R. J. Center, S. J. Kent, I. Stratov. (2011) Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proceedings of the National Academy of Sciences 108:18, 7505-7510
CrossRef147
Filippos Porichis, Daniel E Kaufmann. (2011) HIV-specific CD4 T cells and immune control of viral replication. Current Opinion in HIV and AIDS 6:3, 174-180
CrossRef148
Stanca M. Ciupe, Patrick De Leenheer, Thomas B. Kepler. (2011) Paradoxical suppression of poly-specific broadly neutralizing antibodies in the presence of strain-specific neutralizing antibodies following HIV infection. Journal of Theoretical Biology 277:1, 55-66
CrossRef149
Amina A. Chaudhry, Gail Berkenblit, Allen L. Gifford, Joseph Cofrancesco, James Sosman, Lynn E. Sullivan. (2011) Update in HIV Medicine for the Generalist. Journal of General Internal Medicine 26:5, 538-542
CrossRef150
Brigitte Autran, Benjamin Descours, Véronique Avettand-Fenoel, Christine Rouzioux. (2011) Elite controllers as a model of functional cure. Current Opinion in HIV and AIDS 6:3, 181-187
CrossRef151
B. J. Flynn, K. Kastenmuller, U. Wille-Reece, G. D. Tomaras, M. Alam, R. W. Lindsay, A. M. Salazar, B. Perdiguero, C. E. Gomez, R. Wagner, M. Esteban, C. G. Park, C. Trumpfheller, T. Keler, G. Pantaleo, R. M. Steinman, R. Seder. (2011) Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proceedings of the National Academy of Sciences 108:17, 7131-7136
CrossRef152
Arman A. Bashirova, Rasmi Thomas, Mary Carrington. (2011) HLA/KIR Restraint of HIV: Surviving the Fittest. Annual Review of Immunology 29:1, 295-317
CrossRef153
L. Corey, G. J. Nabel, C. Dieffenbach, P. Gilbert, B. F. Haynes, M. Johnston, J. Kublin, H. C. Lane, G. Pantaleo, L. J. Picker, A. S. Fauci. (2011) HIV-1 Vaccines and Adaptive Trial Designs. Science Translational Medicine 3:79, 79ps13-79ps13
CrossRef154
V. DeGruttola, R. T. Schooley. (2011) Antiretroviral Therapy as Prevention: Linking the Mainframe to Main Street. Clinical Infectious Diseases 52:8, 1050-1052
CrossRef155
P. Spearman, M. A. Lally, M. Elizaga, D. Montefiori, G. D. Tomaras, M. J. McElrath, J. Hural, S. C. De Rosa, A. Sato, Y. Huang, S. E. Frey, P. Sato, J. Donnelly, S. Barnett, L. J. Corey, . (2011) A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers. Journal of Infectious Diseases 203:8, 1165-1173
CrossRef156
Agostino Riva, Elisa Vicenzi, Massimo Galli, Guido Poli. (2011) Strenuous resistance to natural HIV-1 disease progression: viral controllers and long-term nonprogressors. Future Virology 6:4, 521-533
CrossRef157
Amy W. Chung, Marjon Navis, Gamze Isitman, Rob Centre, Robert Finlayson, Mark Bloch, Linda Gelgor, Antony Kelleher, Stephen J Kent, Ivan Stratov. (2011) Activation of NK Cells by ADCC Responses During Early HIV Infection. Viral Immunology 24:2, 171-175
CrossRef158
Niamh Keane, Mina John. (2011) Biomarkers of natural and vaccine immunity against HIV. Biomarkers in Medicine 5:2, 113-116
CrossRef159
P. B. Gilbert, J. O. Berger, D. Stablein, S. Becker, M. Essex, S. M. Hammer, J. H. Kim, V. G. DeGruttola. (2011) Statistical Interpretation of the RV144 HIV Vaccine Efficacy Trial in Thailand: A Case Study for Statistical Issues in Efficacy Trials. Journal of Infectious Diseases 203:7, 969-975
CrossRef160
Ian McGowan. (2011) Rectal Microbicides: Can We Make Them and Will People Use Them?. AIDS and Behavior 15:S1, 66-71
CrossRef161
Marta L. Marthas, Koen K.A. Van Rompay, Zachary Abbott, Patricia Earl, Linda Buonocore-Buzzelli, Bernard Moss, Nina F. Rose, John K. Rose, Pamela A. Kozlowski, Kristina Abel. (2011) Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. Vaccine 29:17, 3124-3137
CrossRef162
D. W. Fitzgerald, H. Janes, M. Robertson, R. Coombs, I. Frank, P. Gilbert, M. Loufty, D. Mehrotra, A. Duerr, . (2011) An Ad5-Vectored HIV-1 Vaccine Elicits Cell-mediated Immunity but does not Affect Disease Progression in HIV-1-infected Male Subjects: Results From a Randomized Placebo-Controlled Trial (The Step Study). Journal of Infectious Diseases 203:6, 765-772
CrossRef163
Edward L. Korn, Boris Freidlin. (2011) Inefficacy Interim Monitoring Procedures in Randomized Clinical Trials: The Need to Report. The American Journal of Bioethics 11:3, 2-10
CrossRef164
Ouzama Nicholson, Fay DiCandilo, James Kublin, Xiao Sun, Erin Quirk, Michelle Miller, Glenda Gray, Jean Pape, Michael N. Robertson, Devan V. Mehrotra, Steven Self, Katherine Turner, Jorge Sanchez, Punnee Pitisuttithum, Ann Duerr, Sheri Dubey, Lisa Kierstead, Danilo Casimiro, Scott M. Hammer. (2011) Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS Research and Human Retroviruses110306081558090
CrossRef165
Marco Salemi. (2011) Toward a robust monitoring of HIV subtypes distribution worldwide. AIDS 25:5, 713-714
CrossRef166
Joris Hemelaar, Eleanor Gouws, Peter D Ghys, Saladin Osmanov. (2011) Global trends in molecular epidemiology of HIV-1 during 2000–2007. AIDS 25:5, 679-689
CrossRef167
P. A. Goepfert, M. L. Elizaga, A. Sato, L. Qin, M. Cardinali, C. M. Hay, J. Hural, S. C. DeRosa, O. D. DeFawe, G. D. Tomaras, D. C. Montefiori, Y. Xu, L. Lai, S. A. Kalams, L. R. Baden, S. E. Frey, W. A. Blattner, L. S. Wyatt, B. Moss, H. L. Robinson, . (2011) Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles. Journal of Infectious Diseases 203:5, 610-619
CrossRef168
Ume L Abbas. (2011) Uptake of biomedical interventions for prevention of sexually transmitted HIV. Current Opinion in HIV and AIDS 6:2, 114-118
CrossRef169
Ann E. Kurth, Connie Celum, Jared M. Baeten, Sten H. Vermund, Judith N. Wasserheit. (2011) Combination HIV Prevention: Significance, Challenges, and Opportunities. Current HIV/AIDS Reports 8:1, 62-72
CrossRef170
Danushka K Wijesundara, Ronald J Jackson, Ian A Ramshaw, Charani Ranasinghe. (2011) Human immunodeficiency virus-1 vaccine design: where do we go now?. Immunology and Cell Biology 89:3, 367-374
CrossRef171
Gamze Isitman, Amy W. Chung, Marjon Navis, Stephen J. Kent, Ivan Stratov. (2011) Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 412:1, 110-116
CrossRef172
E.A. McLaughlin, R.J. Aitken. (2011) Is there a role for immunocontraception?. Molecular and Cellular Endocrinology 335:1, 78-88
CrossRef173
Ashley T. Haase. (2011) Early Events in Sexual Transmission of HIV and SIV and Opportunities for Interventions. Annual Review of Medicine 62:1, 127-139
CrossRef174
E. Van Braeckel, P. Bourguignon, M. Koutsoukos, F. Clement, M. Janssens, I. Carletti, A. Collard, M.-A. Demoitie, G. Voss, G. Leroux-Roels, L. McNally. (2011) An Adjuvanted Polyprotein HIV-1 Vaccine Induces Polyfunctional Cross-Reactive CD4+ T Cell Responses in Seronegative Volunteers. Clinical Infectious Diseases 52:4, 522-531
CrossRef175
M. Juliana McElrath. (2011) Standing Guard at the Mucosa. Immunity 34:2, 146-148
CrossRef176
Mauricio A. Arias, Andrew Loxley, Christy Eatmon, Griet Van Roey, David Fairhurst, Mark Mitchnick, Philip Dash, Tom Cole, Frank Wegmann, Quentin Sattentau, Robin Shattock. (2011) Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen. Vaccine 29:6, 1258-1269
CrossRef177
Andrea R. Thurman, Gustavo F. Doncel. (2011) Innate Immunity and Inflammatory Response to Trichomonas vaginalis and Bacterial Vaginosis: Relationship to HIV Acquisition. American Journal of Reproductive Immunology 65:2, 89-98
CrossRef178
Ioannis Hodges-Mameletzis, GJ De Bree, Sarah L Rowland-Jones. (2011) An underestimated lentivirus model: what can HIV-2 research contribute to the development of an effective HIV-1 vaccine?. Expert Review of Anti-infective Therapy 9:2, 195-206
CrossRef179
Marcio O Lasaro, Larissa H Haut, Xiangyang Zhou, Zhiquan Xiang, Dongming Zhou, Yan Li, Wynetta Giles-Davis, Hua Li, Jessica C Engram, Lauren J DiMenna, Ang Bian, Marina Sazanovich, Elizabeth M Parzych, Raj Kurupati, Juliana C Small, Te-Lang Wu, Rachel M Leskowitz, Nicole R Klatt, Jason M Brenchley, David A Garber, Mark Lewis, Sarah J Ratcliffe, Michael R Betts, Guido Silvestri, Hildegund C Ertl. (2011) Vaccine-induced T cells Provide Partial Protection Against High-dose Rectal SIVmac239 Challenge of Rhesus Macaques. Molecular Therapy 19:2, 417-426
CrossRef180
Morgane Bomsel, Daniela Tudor, Anne-Sophie Drillet, Annette Alfsen, Yonatan Ganor, Marie-Gaëlle Roger, Nicolas Mouz, Mario Amacker, Anick Chalifour, Lorenzo Diomede, Gilles Devillier, Zhe Cong, Qiang Wei, Hong Gao, Chuan Qin, Gui-Bo Yang, Rinaldo Zurbriggen, Lucia Lopalco, Sylvain Fleury. (2011) Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges. Immunity 34:2, 269-280
CrossRef181
Barton F. Haynes, M. Anthony Moody, Hua-Xin Liao, Laurent Verkoczy, Georgia D. Tomaras. (2011) B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends in Molecular Medicine 17:2, 108-116
CrossRef182
Christopher Lai-Hipp, Tiffany Goldberg, Edward Scott, Alyssa Ziman, Girish Vyas. (2011) Pooled peripheral blood mononuclear cells provide an optimized cellular substrate for human immunodeficiency virus Type 1 isolation during acute infection. Transfusion 51:2, 333-337
CrossRef183
Vivek Naranbhai, Quarraisha Abdool Karim, Anna Meyer-Weitz, Vivek Naranbhai. 2011. Interventions to modify sexual risk behaviours for preventing HIV in homeless youth. .
CrossRef184
Stuart N. Isaacs. (2011) A stimulating way to improve T cell responses to poxvirus-vectored vaccines. Journal of Clinical Investigation 121:1, 19-21
CrossRef185
Wibke Bayer, Ruth Lietz, Teona Ontikatze, Lena Johrden, Matthias Tenbusch, Ghulam Nabi, Simone Schimmer, Peter Groitl, Hans Wolf, Cassandra M Berry, Klaus Überla, Ulf Dittmer, Oliver Wildner. (2011) Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology 8:1, 75
CrossRef186
Sarah Brinckmann, Kelly da Costa, Marit J van Gils, David Hallengärd, Katja Klein, Luisa Madeira, Lara Mainetti, Paolo Palma, Katharina Raue, David Reinhart, Marc Reudelsterz, Nicolas Ruffin, Janna Seifried, Katrein Schäfer, Enas Sheik-Khalil, Annette Sköld, Hannes Uchtenhagen, Nicolas Vabret, Serena Ziglio, Gabriella Scarlatti, Robin Shattock, Britta Wahren, Frances Gotch. (2011) Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010. Journal of Translational Medicine 9:1, 40
CrossRef187
Paul Shapshak, Pandjassarame Kangueane, Robert K Fujimura, Deborah Commins, Francesco Chiappelli, Elyse Singer, Andrew J Levine, Alireza Minagar, Francis J Novembre, Charurut Somboonwit, Avindra Nath, John T Sinnott. (2011) Editorial NeuroAIDS review. AIDS 25:2, 123-141
CrossRef188
Richard G Wamai, Brian J Morris, Stefan A Bailis, David Sokal, Jeffrey D Klausner, Ross Appleton, Nelson Sewankambo, David A Cooper, John Bongaarts, Guy de Bruyn, Alex D Wodak, Joya Banerjee. (2011) Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa. Journal of the International AIDS Society 14:1, 49
CrossRef189
Kathleen M MacQueen. (2011) Framing the social in biomedical HIV prevention trials: a 20-year retrospective. Journal of the International AIDS Society 14:Suppl 2, S3
CrossRef190
Laura Papagno, Galit Alter, Lambert Assoumou, Robert L Murphy, Felipe Garcia, Bonaventura Clotet, Martin Larsen, Martine Braibant, Anne-Geneviève Marcelin, Dominique Costagliola, Marcus Altfeld, Christine Katlama, Brigitte Autran. (2011) Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 25:1, 27-36
CrossRef191
George Makedonas, Michael R. Betts. (2011) Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunological Reviews 239:1, 109-124
CrossRef192
Meritxell Genescà. (2011) Characterization of an Effective CTL Response against HIV and SIV Infections. Journal of Biomedicine and Biotechnology 2011, 1-9
CrossRef193
Kazuhiro Matsuo, Yasuhiro Yasutomi. (2011) Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control. Tuberculosis Research and Treatment 2011, 1-9
CrossRef194
Nathan Ford, Alexandra Calmy, Edward J Mills. (2011) The first decade of antiretroviral therapy in Africa. Globalization and Health 7:1, 33
CrossRef195
Elizabeth K Nelson, Britt Piehler, Josh Eckels, Adam Rauch, Matthew Bellew, Peter Hussey, Sarah Ramsay, Cory Nathe, Karl Lum, Kevin Krouse, David Stearns, Brian Connolly, Tom Skillman, Mark Igra. (2011) LabKey Server: An open source platform for scientific data integration, analysis and collaboration. BMC Bioinformatics 12:1, 71
CrossRef196
Luigi Buonaguro, Bali Pulendran. (2011) Immunogenomics and systems biology of vaccines. Immunological Reviews 239:1, 197-208
CrossRef197
Lori L. Heise, Charlotte Watts, Anna Foss, James Trussell, Peter Vickerman, Richard Hayes, Sheena McCormack. (2011) Apples and oranges? Interpreting success in HIV prevention trials. Contraception 83:1, 10-15
CrossRef198
P.A. Newman, S. Yim, A. Daley, R. Walisser, R. Halpenny, W. Cunningham, M. Loutfy. (2011) “Once Bitten, Twice Shy”: Participant perspectives in the aftermath of an early HIV vaccine trial termination. Vaccine 29:3, 451-458
CrossRef199
A. D. Cristillo, M. G. Ferrari, L. Hudacik, B. Lewis, L. Galmin, B. Bowen, D. Thompson, N. Petrovsky, P. Markham, R. Pal. (2011) Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. Journal of General Virology 92:1, 128-140
CrossRef200
Yen-Ju Shen, Enid Shephard, Nicola Douglass, Nicolette Johnston, Craig Adams, Carolyn Williamson, Anna-Lise Williamson. (2011) A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV). Virology Journal 8:1, 265
CrossRef201
Simon H Bridge, Sally A Sharpe, Mike J Dennis, Stuart D Dowall, Brian Getty, Donald S Anson, Michael A Skinner, James P Stewart, Tom J Blanchard. (2011) Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles. Virology Journal 8:1, 429
CrossRef202
David Hallengärd, B. Kristian Haller, Sarah Petersson, Andreas Boberg, Anna-Karin Maltais, Maria Isaguliants, Britta Wahren, Andreas Bråve. (2011) Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity. Vaccine 29:4, 839-848
CrossRef203
Michael, Nelson L., . (2010) Oral Preexposure Prophylaxis for HIV — Another Arrow in the Quiver?. New England Journal of Medicine 363:27, 2663-2665
Full Text204
A. Mader, R. Kunert. (2010) Humanization strategies for an anti-idiotypic antibody mimicking HIV-1 gp41. Protein Engineering Design and Selection 23:12, 947-954
CrossRef205
Gary Frey, Jia Chen, Sophia Rits-Volloch, Michael M Freeman, Susan Zolla-Pazner, Bing Chen. (2010) Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nature Structural & Molecular Biology 17:12, 1486-1491
CrossRef206
J. Ambrosioni, G. Andreani, C. Acuipil, R. Barral, R. Rabinovich, Liliana Martinez Peralta. (2010) Comparative reactivity of serum samples from Argentinean HIV-infected patients with V3 peptides from subtype B or BF recombinants. Archives of Virology 155:12, 2029-2034
CrossRef207
Susan M Fetherston, R Karl Malcolm, A David Woolfson. (2010) Controlled-release vaginal ring drug-delivery systems: a key strategy for the development of effective HIV microbicides. Therapeutic Delivery 1:6, 785-802
CrossRef208
Sally L Hodder, Jessica Justman, Danielle F Haley, Adaora A Adimora, Catherine I Fogel, Carol E Golin, Ann OʼLeary, Lydia Soto-Torres, Gina Wingood, Wafaa M El-Sadr. (2010) Challenges of a Hidden Epidemic: HIV Prevention Among Women in the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes 55, S69-S73
CrossRef209
Barb Lohman-Payne, Jennifer Slyker, Sarah L. Rowland-Jones. (2010) Immune-based Approaches to the Prevention of Mother-to-child Transmission of HIV-1: Active and Passive Immunization. Clinics in Perinatology 37:4, 787-805
CrossRef210
Geetha P. Bansal, Wolfgang W. Leitner. (2010) Innate immunity in HIV infection and implications for vaccine design: A summary of the workshop held at the National Institute of Allergy and Infectious Diseases, Bethesda on February 25–26, 2010. Vaccine 28:52, 8229-8235
CrossRef211
Jonathan D Fuchs, Magda E Sobieszczyk, Scott M Hammer, Susan P Buchbinder. (2010) Lessons Drawn From Recent HIV Vaccine Efficacy Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes 55, S128-S131
CrossRef212
Gregorio A Millett, Jeffrey S Crowley, Howard Koh, Ronald O Valdiserri, Thomas Frieden, Carl W Dieffenbach, Kevin A. Fenton, Regina Benjamin, Jack Whitescarver, Jonathan Mermin, Deborah Parham-Hopson, Anthony S Fauci. (2010) A Way Forward: The National HIV/AIDS Strategy and Reducing HIV Incidence in the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes 55, S144-S147
CrossRef213
Philip L. Bulterys, Sudeb C. Dalai, David A. Katzenstein. (2010) Viral Sequence Analysis from HIV-Infected Mothers and Infants: Molecular Evolution, Diversity, and Risk Factors for Mother-To-Child Transmission. Clinics in Perinatology 37:4, 739-750
CrossRef214
Michael M. Freeman, Michael S. Seaman, Sophia Rits-Volloch, Xinguo Hong, Chia-Ying Kao, David D. Ho, Bing Chen. (2010) Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody. Structure 18:12, 1632-1641
CrossRef215
Tara G. Edmonds, Haitao Ding, Xing Yuan, Qing Wei, Kendra S. Smith, Joan A. Conway, Lindsay Wieczorek, Bruce Brown, Victoria Polonis, John T. West, David C. Montefiori, John C. Kappes, Christina Ochsenbauer. (2010) Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408:1, 1-13
CrossRef216
Damien Z Soghoian, Hendrik Streeck. (2010) Cytolytic CD4 + T cells in viral immunity. Expert Review of Vaccines 9:12, 1453-1463
CrossRef217
H. Dreja, E. O'Sullivan, C. Pade, K. M. Greene, H. Gao, K. Aubin, J. Hand, A. Isaksen, C. D'Souza, W. Leber, D. Montefiori, M. S. Seaman, J. Anderson, C. Orkin, A. McKnight. (2010) Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. Journal of General Virology 91:11, 2794-2803
CrossRef218
Antonella Caivano, Nicole A. Doria-Rose, Benjamin Buelow, Rossella Sartorius, Maria Trovato, Luciana D'Apice, Gonzalo J. Domingo, William F. Sutton, Nancy L. Haigwood, Piergiuseppe De Berardinis. (2010) HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells. Virology 407:2, 296-305
CrossRef219
M R Nicol, A D M Kashuba. (2010) Pharmacologic Opportunities for HIV Prevention. Clinical Pharmacology & Therapeutics 88:5, 598-609
CrossRef220
Shirui Li, Xiangrong Qi, Yingying Gao, Yanling Hao, Lianxian Cui, Li Ruan, Wei He. (2010) IL-15 increases the frequency of effector memory CD8+ T cells in rhesus monkeys immunized with HIV vaccine. Cellular and Molecular Immunology 7:6, 491-494
CrossRef221
George B Cohen. (2010) HIV vaccines: sin boldly!. AIDS 24:18, 2877-2879
CrossRef222
Peter S. Kim, Sarah W. Read. (2010) Nanotechnology and HIV: potential applications for treatment and prevention. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 2:6, 693-702
CrossRef223
Isabel Leroux-Roels, Marguerite Koutsoukos, Frédéric Clement, Sophia Steyaert, Michel Janssens, Patricia Bourguignon, Kristen Cohen, Marcus Altfeld, Pierre Vandepapelière, Louise Pedneault, Lisa McNally, Geert Leroux-Roels, Gerald Voss. (2010) Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine 28:43, 7016-7024
CrossRef224
Catherine A Hankins, Barbara O de Zalduondo. (2010) Combination prevention: a deeper understanding of effective HIV prevention. AIDS 24:Suppl 4, S70-S80
CrossRef225
Gambo Aliyu, Mukhtar Mohammad, Ahmed Saidu, Prosanta Mondal, Man Charurat, Alash'le Abimiku, Abdulsalami Nasidi, William Blattner. (2010) HIV infection awareness and willingness to participate in future HIV vaccine trials across different risk groups in Abuja, Nigeria. AIDS Care 22:10, 1277-1284
CrossRef226
Philip Hunter. (2010) Vaccine outlooks. EMBO reports 11:10, 738-741
CrossRef227
Jonathan Weber, Roger Tatoud, Sarah Fidler. (2010) Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission. AIDS 24:Suppl 4, S27-S39
CrossRef228
Z Mike Chirenje, Jeanne Marrazzo, Urvi M Parikh. (2010) Antiretroviral-based HIV prevention strategies for women. Expert Review of Anti-infective Therapy 8:10, 1177-1186
CrossRef229
John M Kaldor, David P Wilson. (2010) How low can you go: the impact of a modestly effective HIV vaccine compared with male circumcision. AIDS 24:16, 2573-2578
CrossRef230
Carlo Zanotto, Eleana Pozzi, Sole Pacchioni, Luca Volonté, Carlo De Giuli Morghen, Antonia Radaelli. (2010) Canarypox and fowlpox viruses as recombinant vaccine vectors: A biological and immunological comparison. Antiviral Research 88:1, 53-63
CrossRef231
Richard Hayes, Saidi Kapiga, Nancy Padian, Sheena McCormack, Judith Wasserheit. (2010) HIV prevention research: taking stock and the way forward. AIDS 24:Suppl 4, S81-S92
CrossRef232
Kuan-Hsiang G. Huang, David Bonsall, Aris Katzourakis, Emma C. Thomson, Sarah J. Fidler, Janice Main, David Muir, Jonathan N. Weber, Alexander J. Frater, Rodney E. Phillips, Oliver G. Pybus, Philip J.R. Goulder, Myra O. McClure, Graham S. Cooke, Paul Klenerman. (2010) B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nature Communications 1:7, 102
CrossRef233
Patricia E Fast, Pontiano Kaleebu. (2010) HIV vaccines: current status worldwide and in Africa. AIDS 24:Suppl 4, S50-S60
CrossRef234
Q. Abdool Karim, S. S. Abdool Karim, J. A. Frohlich, A. C. Grobler, C. Baxter, L. E. Mansoor, A. B. M. Kharsany, S. Sibeko, K. P. Mlisana, Z. Omar, T. N. Gengiah, S. Maarschalk, N. Arulappan, M. Mlotshwa, L. Morris, D. Taylor, . (2010) Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 329:5996, 1168-1174
CrossRef235
Seth Berkley, Kenneth Bertram, Jean-François Delfraissy, Ruxandra Draghia-Akli, Anthony Fauci, Cynthia Hallenbeck, Madame Jeannette Kagame, Peter Kim, Daisy Mafubelu, Malegapuru W Makgoba, Peter Piot, Mark Walport, Mitchell Warren, Tadataka Yamada, José Esparza, Catherine Hankins, Margaret I Johnston, Yves Lévy, Manuel Romaris, Rafi Ahmed, Alan Bernstein. (2010) The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. Nature Medicine 16:9, 981-989
CrossRef236
Yegor Voronin, Amapola Manrique, Alan Bernstein. (2010) The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise. Current Opinion in HIV and AIDS 5:5, 414-420
CrossRef237
Daniela Teixeira, Patricia Munerato, Shirley Cavalcante Vasconcelos Komninakis, Erika Etsuko Fusuma, Luiz Mario Janini, Maria Cecilia Araripe Sucupira, Ricardo Sobhie Diaz. (2010) The Detection of in Vivo and in Vitro HIV Type 1 B/F Profiles in Brazil Using a Real-Time PCR Assay for Five HIV Type 1 Genomic Regions. AIDS Research and Human Retroviruses 26:9, 981-990
CrossRef238
Giuseppe Pantaleo, Mariano Esteban, Bertram Jacobs, Jim Tartaglia. (2010) Poxvirus vector-based HIV vaccines. Current Opinion in HIV and AIDS 5:5, 391-396
CrossRef239
Yegor Voronin, Sanjay Phogat. (2010) HIV/AIDS: vaccines and alternate strategies for treatment and prevention. Annals of the New York Academy of Sciences 1205, E1-E9
CrossRef240
Robert M Paris, Jerome H Kim, Merlin L Robb, Nelson L Michael. (2010) Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Review of Vaccines 9:9, 1055-1069
CrossRef241
Sudhir Paul, Stephanie Planque, Yasuhiro Nishiyama, Miguel Escobar, Carl Hanson. (2010) Back to the future: covalent epitope-based HIV vaccine development. Expert Review of Vaccines 9:9, 1027-1043
CrossRef242
Monica Vaccari, Poonam Poonam, Genoveffa Franchini. (2010) Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Review of Vaccines 9:9, 997-1005
CrossRef243
Dan H Barouch. (2010) Novel adenovirus vector-based vaccines for HIV-1. Current Opinion in HIV and AIDS 5:5, 386-390
CrossRef244
Silvija I Staprans, Mark B Feinberg, John W Shiver, Danilo R Casimiro. (2010) Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective. Current Opinion in HIV and AIDS 5:5, 377-385
CrossRef245
Barton F Haynes, Hua-Xin Liao, Georgia D Tomaras. (2010) Is developing an HIV-1 vaccine possible?. Current Opinion in HIV and AIDS 5:5, 362-367
CrossRef246
Jerome H Kim, Supachai Rerks-Ngarm, Jean-Louis Excler, Nelson L Michael. (2010) HIV vaccines: lessons learned and the way forward. Current Opinion in HIV and AIDS 5:5, 428-434
CrossRef247
Kazuhiro Matsuo, Naoki Yamamoto. (2010) Paradigm change in immune correlation: cellular or humoral?. Expert Review of Vaccines 9:9, 985-987
CrossRef248
Ann Duerr. (2010) Update on mucosal HIV vaccine vectors. Current Opinion in HIV and AIDS 5:5, 397-403
CrossRef249
Dominique Salmon-Céron, Christine Durier, Corinne Desaint, Lise Cuzin, Mathieu Surenaud, Nadine Ben Hamouda, Jean-Daniel Lelièvre, Bénédicte Bonnet, Gilles Pialoux, Isabelle Poizot-Martin, Jean-Pierre Aboulker, Yves Lévy, Odile Launay. (2010) Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS 24:14, 2211-2223
CrossRef250
Harel Dahari, Stephen M. Feinstone, Marian E. Major. (2010) Meta-Analysis of Hepatitis C Virus Vaccine Efficacy in Chimpanzees Indicates an Importance for Structural Proteins. Gastroenterology 139:3, 965-974
CrossRef251
Georgia D Tomaras, Barton F Haynes. (2010) Strategies for eliciting HIV-1 inhibitory antibodies. Current Opinion in HIV and AIDS 5:5, 421-427
CrossRef252
Tomáš Hanke. (2010) On the growing complexity of HIV-1 vaccines. HIV Therapy 4:5, 543-552
CrossRef253
Maxim Totrov, Xunqing Jiang, Xiang-Peng Kong, Sandra Cohen, Chavdar Krachmarov, Aidy Salomon, Constance Williams, Michael S. Seaman, Timothy Cardozo, Miroslaw K. Gorny, Shixia Wang, Shan Lu, Abraham Pinter, Susan Zolla-Pazner. (2010) Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology 405:2, 513-523
CrossRef254
Hélène Perrin, Glenda Canderan, Rafick-Pierre Sékaly, Lydie Trautmann. (2010) New approaches to design HIV-1 T-cell vaccines. Current Opinion in HIV and AIDS 5:5, 368-376
CrossRef255
Joseph G Joyce, Jan ter Meulen. (2010) Pushing the envelope on HIV-1 neutralization. Nature Biotechnology 28:9, 929-931
CrossRef256
C. Sundling, M. N. E. Forsell, S. O'Dell, Y. Feng, B. Chakrabarti, S. S. Rao, K. Lore, J. R. Mascola, R. T. Wyatt, I. Douagi, G. B. Karlsson Hedestam. (2010) Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. Journal of Experimental Medicine 207:9, 2003-2017
CrossRef257
K. J. Doores, C. Bonomelli, D. J. Harvey, S. Vasiljevic, R. A. Dwek, D. R. Burton, M. Crispin, C. N. Scanlan. (2010) Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proceedings of the National Academy of Sciences 107:31, 13800-13805
CrossRef258
Fred Zepp. (2010) Principles of vaccine design—Lessons from nature. Vaccine 28, C14-C24
CrossRef259
Anatoli Kamali. (2010) What is new in HIV/AIDS research in developing countries?. Tropical Medicine & International Health 15:8, 975-980
CrossRef260
Nunzia Scotti, Luigi Buonaguro, Maria Lina Tornesello, Teodoro Cardi, Franco Maria Buonaguro. (2010) Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches. Expert Review of Vaccines 9:8, 925-936
CrossRef261
Ralph M. Steinman. (2010) Some active areas of DC research and their medical potential. European Journal of Immunology 40:8, 2085-2088
CrossRef262
Koff, Wayne C., Berkley, Seth F., . (2010) The Renaissance in HIV Vaccine Development — Future Directions. New England Journal of Medicine 363:5,
Full Text263
Cassandra Willyard. (2010) Tiny steps towards an HIV vaccine. Nature 466:7304, S8-S8
CrossRef264
Susan Zolla-Pazner, Timothy Cardozo. (2010) Structure–function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nature Reviews Immunology 10:7, 527-535
CrossRef265
Sacha Gnjatic, Nikhil B. Sawhney, Nina Bhardwaj. (2010) Toll-Like Receptor Agonists. The Cancer Journal 16:4, 382-391
CrossRef266
Myron S Cohen, Sarah Fidler. (2010) HIV prevention 2010: where are we now and where are we going?. Current Opinion in HIV and AIDS 5:4, 265-268
CrossRef267
Eric Y Wong, Indira K Hewlett. (2010) HIV diagnostics: challenges and opportunities. HIV Therapy 4:4, 399-412
CrossRef268
Reuben Granich, Siobhan Crowley, Marco Vitoria, Caoimhe Smyth, James G Kahn, Rod Bennett, Ying-Ru Lo, Yves Souteyrand, Brian Williams. (2010) Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Current Opinion in HIV and AIDS 5:4, 298-304
CrossRef269
Olamide Dosekun, Julie Fox. (2010) An overview of the relative risks of different sexual behaviours on HIV transmission. Current Opinion in HIV and AIDS 5:4, 291-297
CrossRef270
George K Lewis. (2010) Challenges of antibody-mediated protection against HIV-1. Expert Review of Vaccines 9:7, 683-687
CrossRef271
Jose J Reina, Anna Bernardi, Mario Clerici, Javier Rojo. (2010) HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors. Future Medicinal Chemistry 2:7, 1141-1159
CrossRef272
Brandon F Keele. (2010) Identifying and characterizing recently transmitted viruses. Current Opinion in HIV and AIDS 5:4, 327-334
CrossRef273
Bill G Kapogiannis, Ed Handelsman, Monica S Ruiz, Sonia Lee. (2010) Introduction: Paving the Way for Biomedical HIV Prevention Interventions in Youth. JAIDS Journal of Acquired Immune Deficiency Syndromes 54, S1-S4
CrossRef274
Stephen D Barr. (2010) Cellular HIV-1 restriction factors: a new avenue for AIDS therapy?. Future Virology 5:4, 417-433
CrossRef275
Bret J Rudy, Bill G Kapogiannis, Michelle A Lally, Glenda E Gray, Linda-Gail Bekker, Paul Krogstad, Ian McGowan. (2010) Youth-Specific Considerations in the Development of Preexposure Prophylaxis, Microbicide, and Vaccine Research Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes 54, S31-S42
CrossRef276
Carol A. Marzetta, Stephen S. Lee, Sandra J. Wrobel, Kanwarjit J. Singh, Nina Russell, José Esparza. (2010) The potential global market size and public health value of an HIV-1 vaccine in a complex global market. Vaccine 28:30, 4786-4797
CrossRef277
Peter A Newman, Carmen Logie. (2010) HIV vaccine acceptability: a systematic review and meta-analysis. AIDS 24:11, 1749-1756
CrossRef278
E. Bianchi, J. G. Joyce, M. D. Miller, A. C. Finnefrock, X. Liang, M. Finotto, P. Ingallinella, P. McKenna, M. Citron, E. Ottinger, R. W. Hepler, R. Hrin, D. Nahas, C. Wu, D. Montefiori, J. W. Shiver, A. Pessi, P. S. Kim. (2010) Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proceedings of the National Academy of Sciences 107:23, 10655-10660
CrossRef279
Rupert Kaul, Kelly S MacDonald, Nico J Nagelkerke, Joshua Kimani, Keith Fowke, T Blake Ball, Ma Luo, Anthony Kariri, Walter Jaoko, Stephen Moses, Sarah Rowland-Jones, Francis A Plummer. (2010) HIV viral set point and host immune control in individuals with HIV-specific CD8+ T-cell responses prior to HIV acquisition. AIDS 24:10, 1449-1454
CrossRef280
Laura M Walker, Dennis R Burton. (2010) Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Current Opinion in Immunology 22:3, 358-366
CrossRef281
Hildegund CJ Ertl, Antonio Lanzavecchia. (2010) Introduction. Current Opinion in Immunology 22:3, 355-357
CrossRef282
Anna Laura Ross, Andreas Bråve, Gabriella Scarlatti, Amapola Manrique, Luigi Buonaguro. (2010) Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. The Lancet Infectious Diseases 10:5, 305-316
CrossRef283
Barton F Haynes, Nathan I Nicely, S Munir Alam. (2010) HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention?. Nature Structural & Molecular Biology 17:5, 543-545
CrossRef284
Vicky Jespers, Ali M Harandi, Jorma Hinkula, Donata Medaglini, Roger Le Grand, Christiane Stahl-Hennig, Willy Bogers, Raphaelle El Habib, Frank Wegmann, Carol Fraser, Martin Cranage, Robin J Shattock, Anna-Lena Spetz. (2010) Assessment of mucosal immunity to HIV-1. Expert Review of Vaccines 9:4, 381-394
CrossRef285
A. L. Goodman, S. J. Draper. (2010) Blood-stage malaria vaccines — recent progress and future challenges. Annals of Tropical Medicine and Parasitology 104:3, 189-211
CrossRef286
Herbert W. Virgin, Bruce D. Walker. (2010) Immunology and the elusive AIDS vaccine. Nature 464:7286, 224-231
CrossRef287
Ashley T. Haase. (2010) Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464:7286, 217-223
CrossRef288
Wayne C. Koff. (2010) Accelerating HIV vaccine development. Nature 464:7286, 161-162
CrossRef289
George B Cohen. (2010) Mechanism of protection of live attenuated simian immunodeficiency virus: coevolution of viral and immune responses. AIDS 24:5, 637-648
CrossRef290
John R. Mascola, David C. Montefiori. (2010) The Role of Antibodies in HIV Vaccines. Annual Review of Immunology 28:1, 413-444
CrossRef291
Lawrence Corey, M Juliana McElrath. (2010) HIV vaccines: mosaic approach to virus diversity. Nature Medicine 16:3, 268-270
CrossRef292
Stephanie Planque, Maria Salas, Yukie Mitsuda, Marcin Sienczyk, Miguel A Escobar, Jason P Mooney, Mary-Kate Morris, Yasuhiro Nishiyama, Dipanjan Ghosh, Amit Kumar, Feng Gao, Carl V Hanson, Sudhir Paul. (2010) Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120–CD4-binding site from long-term survivors of HIV infection. AIDS 24:6, 875-884
CrossRef293
Andreas Brave, Ulrika Johansson, David Hallengärd, Shirin Heidari, Hanna Gullberg, Britta Wahren, Jorma Hinkula, Anna-Lena Spetz. (2010) Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes. Vaccine 28:9, 2080-2087
CrossRef294
Linda L. Baum. (2010) Role of Humoral Immunity in Host Defense Against HIV. Current HIV/AIDS Reports 7:1, 11-18
CrossRef295
Koen K.A. Van Rompay, Kristina Abel, Patricia Earl, Pamela A. Kozlowski, Juliet Easlick, Joseph Moore, Linda Buonocore-Buzzelli, Kimberli A. Schmidt, Robert L. Wilson, Ian Simon, Bernard Moss, Nina Rose, John Rose, Marta L. Marthas. (2010) Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: Attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. Vaccine 28:6, 1481-1492
CrossRef296
Duk-Jae Han, David B. Weiner, Jeong-Im Sin. (2010) DNA Vaccines against Infectious Diseases and Cancer. Biomolecules and Therapeutics 18:1, 1-15
CrossRef297
A. Bansal, J. Carlson, J. Yan, O. T. Akinsiku, M. Schaefer, S. Sabbaj, A. Bet, D. N. Levy, S. Heath, J. Tang, R. A. Kaslow, B. D. Walker, T. Ndung'u, P. J. Goulder, D. Heckerman, E. Hunter, P. A. Goepfert. (2010) CD8 T cell response and evolutionary pressure to HIV-1 cryptic epitopes derived from antisense transcription. Journal of Experimental Medicine 207:1, 51-59
CrossRef298
J. G. Garcia-Lerma, M.-e. Cong, J. Mitchell, A. S. Youngpairoj, Q. Zheng, S. Masciotra, A. Martin, Z. Kuklenyik, A. Holder, J. Lipscomb, C.-P. Pau, J. R. Barr, D. L. Hanson, R. Otten, L. Paxton, T. M. Folks, W. Heneine. (2010) Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection. Science Translational Medicine 2:14, 14ra4-14ra4
CrossRef299
Richard A. Koup, Barney S. Graham, Daniel C. Douek. (2010) The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nature Reviews Immunology 11:1, 65-70
CrossRef300
José A. Esté, Tomas Cihlar. (2010) Current status and challenges of antiretroviral research and therapy. Antiviral Research 85:1, 25-33
CrossRef301
Damien V. Cordery, David A. Cooper. (2010) Clinical research in NSW: its role in HIV care and prevention. New South Wales Public Health Bulletin 21:4, 93
CrossRef302
Ingrid T. Katz, Norma C. Ware, Glenda Gray, Jessica E. Haberer, Claude A. Mellins, David R. Bangsberg. (2010) Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence. Sexual Health 7:3, 279
CrossRef303
Peter A. Newman, Surachet Roungprakhon, Suchon Tepjan, Suzy Yim. (2010) Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine 28:4, 958-964
CrossRef304
Dolin, Raphael, . (2009) HIV Vaccine Trial Results — An Opening for Further Research. New England Journal of Medicine 361:23, 2279-2280
Full Text305
N. L. Letvin. (2009) Moving Forward in HIV Vaccine Development. Science 326:5957, 1196-1198
CrossRef
